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ABSTRACT 
Cardiovascular development and its proper function are essential for the development and 
survival of animals, while malformation of vasculature leads to a variety of diseases.  The 
significance of vasculature during development and in adulthood has been delineated by 
investigating the functions of genes expressed in the vasculature.  Endothelial cells lining 
the lumen of vessel tubes with a single layer, had long been considered inert, 
homogeneous cells.  However, molecular and genetic studies have provided numerous 
pieces of evidence, which indicate that endothelial cells are active, dynamic, 
heterogeneous cells.  Among these studies, molecular differences between arterial and 
venous endothelial cells were first revealed by the observation that ephrin-B2 and its 
cognate receptor EphB4 are restrictively expressed in arterial and venous endothelial 
cells, respectively.  These genes are not only molecular markers of arteries and veins, but 
they also play essential roles in cardiovascular development. 
To investigate whether the molecular difference between arteries and veins persists 
into adulthood, I analyzed ephrin-B2 expression in adult tissues including pathological 
settings.  These data indicate that the molecular distinction is maintained in adults, and 
ephrin-B2 further distinguishes arterial smooth muscle cells from venous smooth muscle 
cells in adults. 
Ephrin-B2 was serendipitously identified as an arterial marker; therefore, I performed 
a systematic screen to isolate novel arterial- and venous-specific genes, whose 
identification and characterization might improve current understanding of vascular 
biology.  Through this screen, I isolated several novel arterial-restricted genes, and one of 
these genes, Depp (decidual protein induced by progesterone), was characterized in detail 
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by generating a knockout of the Depp locus.  Although the homozygous mutant mice 
appear phenotypically normal, the detailed analysis of Depp expression reveals the 
heterogeneity of arterial endothelial cells from the early stage of vascular development. 
I identified another novel gene, D1.1, through the screen; however, D1.1 is expressed 
in both arterial and venous endothelial cells.  The fact that D1.1 is specifically expressed 
in endothelial cells and encodes a predicted transmembrane protein, prompted me to 
characterize D1.1 in detail using a tau-LacZ knock-in to the D1.1 locus.  The data from 
the expression analysis suggest D1.1 as a novel marker of adult neovasculature.  In 
addition, the data using a soluble D1.1-Fc fusion protein in several different acute assays 
suggest that D1.1 may play a functional role in angiogenesis that is compensated in vivo 
by other, structurally distinct proteins. 
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Introduction 
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The proper vascular formation, which occurs by two distinct mechanisms, vasculogenesis 
and angiogenesis, is essential for embryonic development.  Vasculogenesis is the 
mechanism responsible for generating primary vascular plexus from endothelial 
progenitor cells or angioblasts (vascular endothelial cells that have not incorporated into 
vessels); angiogenesis is the mechanism responsible for generating blood vessels from 
the pre-existing vessels and to remodel the primary vascular plexus into an arborized 
network of large and small vessels (Risau, 1997).  Many genes implicated in 
vasculogenesis and angiogenesis have been identified by targeted gene inactivation in 
mice; those well characterized include members of vascular endothelial growth factor 
(VEGF) family and their tyrosine kinase receptors, the angiopoietins and their tyrosine 
kinase receptors, and some members of the ephrin-B family and their Eph-B tyrosine 
kinase receptors (Harvey and Oliver, 2004).   
Mice lacking the VEGF receptor Flk1 do not have endothelial or hematopoietic cells 
in embryos, suggesting an essential role of Flk1 and its ligands (VEGF) in the 
development of both cell lineages (Shalaby et al., 1995).  Mice lacking VEGF-A, a ligand 
of Flk1, show vascular defects such as reduced endothelial cell differentiation, aberrant 
angiogenic remodeling and vessel patterning, absence of large vessels, and defective 
endothelial interconnections (Carmeliet et al., 1996; Ferrara et al., 1996).  Heterozygous 
VEGF-A mutant embryos also show vascular defects, to a lesser extent, and are 
embryonic lethal, suggesting that the level of VEGF-A expression is crucial for proper 
vascular development (Carmeliet et al., 1996; Ferrara et al., 1996).  Additionally, the 
VEGF co-receptors, neuropilin-1 (NP-1) and neuropilin-2 (NP-2), are essential for 
 
   3
vascular development, as revealed by the fact that the genetic ablation of both genes 
results in vascular defects and early embryonic lethality (Takashima et al., 2002). 
Mice lacking Tie2, an angiopoietin receptor, display severe cardiovascular defects and 
die around E9.5 (Sato et al., 1995).  Vasculogenesis in the yolk sac and embryo occurs 
normally, but subsequent angiogenesis steps are absent or greatly retarded (Sato et al., 
1995).  Angiopoietin-1, a ligand of Tie2, homozygous mutant mice also show severe 
cardiovascular defects similar to those of the Tie2 homozygous mutant mice, suggesting 
the essential roles of angiopoietin/Tie2 signaling in the proper cardiovascular 
development (Suri et al., 1996). 
Ephrin-B2 and its tyrosine kinase receptor EphB4 are restrictively expressed in arterial 
and venous endothelial cells, respectively (Gerety et al., 1999; Wang et al., 1998).  
Ephrin-B2 and EphB4 homozygous mutant mice display similar cardiovascular defects, 
suggesting that ephrin-B2/EphB4 signaling is essential for proper vascular development 
(Adams et al., 1999; Gerety et al., 1999; Wang et al., 1998).  Additionally, EphB2/EphB3 
double homozygous mutant mice show similar angiogenesis defects, albeit with a low 
penetrance (Adams et al., 1999).   
Pericytes and vascular smooth muscle cells (vSMC) play important roles in the 
formation of proper vasculature (Gerhardt and Betsholtz, 2003).  During angiogenesis, 
platelet-derived growth factor-B (PDGF-B) and its receptor PDGFR-β are expressed in 
the sprouting endothelial cells and pericyte/vSMC progenitors, respectively, suggesting a 
paracrine interaction between endothelial cells and pericyte/vSMA progenitors.  Genetic 
ablation of PDGF-B and its receptor PDGFR-β in mice display similar phenotypes, such 
as widespread microvascular leakage and hemorrhage and reduced pericyte proliferation, 
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supporting the paracrine interaction between the two cell types (Leveen et al., 1994; 
Lindahl et al., 1997; Soriano, 1994).  Moreover, the endothelial specific knockout of 
PDGF-B results in pericyte/vSMC deficiency (Enge et al., 2002).  These data suggest that 
PDGF-B and PDGFR-β play an essential role in the recruitment of pericytes/vSMCs to 
newly formed vessels.  In addition to PDGF-B/PDGFR-β signaling, angiopoietin-1/Tie-2 
signaling is involved in the recruitment of pericytes, which secrete angiopoitin-1 (Sato et 
al., 1995; Suri et al., 1996).   
 
Molecular differences between arteries and veins 
The continuous blood vascular networks are divided into arteries, carrying blood away 
from the heart; and veins, carrying blood toward the heart.  In addition to the functional 
distinction, arteries are distinguished from veins in terms of physiology and morphology.  
Arteries contain more oxygen and nutrition than veins, while veins contain more CO2 and 
waste products.  Arteries receive higher blood pressure and shear stress than veins.  
Moreover, arteries are more elastic and contain more smooth muscle cell layers than 
veins, while only veins contain valves to prevent the back-flow of the blood stream.  
While these physiological and morphological differences have been known for several 
centuries, molecular differences between arteries and veins have only been recently 
reported.  Ephrin-B2 is specifically expressed in arterial endothelial cells, whereas its 
cognate receptor tyrosine kinase EphB4 is restrictively expressed in venous endothelial 
cells from the early cardiovascular development (Gerety et al., 1999; Wang et al., 1998).  
Since the first identification of arterial-specific gene ephrin-B2, many other arterial-
specific or restricted genes have been identified. Notch receptors and its ligands including 
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Notch1, Notch3, Notch4, Dll4, Jagged1 and Jagged2 are expressed in arteries but not in 
veins (Shutter et al., 2000; Villa et al., 2001); Hey1-3, a family of basic helix-loop-helix 
(bHLH) transcription factors and direct targets of the Notch signaling pathway, are 
restrictively expressed in arteries (Leimeister et al., 1999; Nakagawa et al., 1999).  
Activin receptor-like kinase 1 (Alk1), a type I receptor for TGF-β family proteins (Urness 
et al., 2000); EPAS-1, a close relative of the hypoxia-inducible factor 1α transcription 
factor (Tian et al., 1997); and the netrin receptor UNC5B are restrictively expressed in 
arterial endothelial cells (Lu et al., 2004). 
These genes are not only restrictively expressed in arterial endothelial cells, but also 
play essential roles in the proper vascular development.  For example, Notch1 
homozygous mutant mice show severe defects in angiogenic vascular remodeling.  
Notch1/Notch4 double homozygous mutant embryos display a more severe phenotype 
than Notch1 homozygous mutant embryos even though Notch4 homozygous mutant 
embryos show no vascular defects, suggesting that Notch4 is also play important role in 
angiogenesis (Krebs et al., 2000).  The endothelial specific genetic ablation of Notch1 
recapitulates the vascular phenotype of conventional Notch1 homozygous mutant mice, 
indicating an essential role of Notch1 signaling in endothelial cells during vascular 
development (Limbourg et al., 2005).  Dll4 ligand heterozygous mutant embryos display 
severe angiogenesis defects similar to Notch1 mutants, suggesting that Dll4 is essential in 
a dosage-sensitive manner for the proper vascular development (Duarte et al., 2004; Gale 
et al., 2004; Krebs et al., 2004).  The combined genetic ablation of Hey1 and Hey2 results 
in severe vascular defects reminiscent of Notch1 mutant defects, suggesting that Hey1 
and Hey2 are the main downstream targets of Notch signaling in endothelial cells 
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(Fischer et al., 2004; Kokubo et al., 2005).  Alk1 homozygous mutant mice display severe 
arteriovenous malformations, resulting from fusion of major arteries and veins, and 
severe angiogenesis defects (Urness et al., 2000).  UNC2B homozygous mutant mice 
show aberrant extension of endothelial tip cell filopodia, excessive vessels branching and 
abnormal navigation, although patterning of the major vessels is largely normal (Lu et al., 
2004).  
In addition to the molecular differences between arterial and venous endothelial cells, 
there are molecular differences between arterial and venous SMCs, although these 
differences have not been as well reported.  EVEC/DANCE, an EGF-like-repeat-
containing secreted protein, is expressed in arterial SMCs during development, and is 
virtually undetectable in adult arterial SMCs, although it can be reinduced upon injury 
(Kowal et al., 1999; Nakamura et al., 1999).  The “latent TGFβ-binding protein-2” 
(LTBP-2) is expressed in arterial SMCs during development (Fang et al., 1997), and it is 
not clear whether its expression persists into adulthood. Ephrin-B2 is preferentially 
expressed in arterial SMCs as well as in arterial endothelial cells; the onset of ephrin-B2 
expression in arterial SMCs occurs at E12.5 and its expression persists into adulthood 
(Shin et al., 2001).  Interestingly, several Notch receptors and its ligands are expressed in 
arterial SMCs but not in venous SMCs (Villa et al., 2001), suggesting the possibility that 
Notch signaling may play a important role in arterial SMCs like it does in arterial 
endothelial cells. 
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Specification of arteries and veins 
Although ephrin-B2 and EphB4 in mice are essential for the proper formation of arteries 
and veins, the fact that ephrin-B2 homozygous mutant mice still express ephrin-B2 in the 
arterial endothelial cells, indicates that these genes are not involved in the initial 
specification of arterial and venous endothelial cells (Gerety et al., 1999; Wang et al., 
1998).  What are the upstream factors to induce ephrin-B2 in arteries and EphB4 in 
veins? 
Recent studies in zebrafish and mice have provided evidence that Notch signaling is 
the upstream mechanism that induces arterial specification (Weinstein and Lawson, 
2002).  In zebrafish, notch5 and deltaC are specifically expressed in arterial endothelial 
cells (Kortschak et al., 2001; Smithers et al., 2000), suggesting that Notch might play an 
important role in the artery formation.  Gain-of-function and loss-of-function studies in 
zebrafish using mindbomb mutants (where Notch signaling is genetically reduced), a 
dominant-negative DNA-binding mutant of Xenopus suppressor of hairless protein, and a 
constitutive-active Notch intracellular domain, reveal that Notch signaling promotes 
arterial differentiation at the expense of venous differentiation during vascular 
development (Lawson et al., 2001).  The murine studies, using targeted ablation of genes 
involved in the Notch signaling pathway, result in the loss of the expression of arterial 
markers including ephrin-B2, in Dll4 homozygous mutant embryos (Duarte et al., 2004), 
in Hey1/Hey2 double homozygous mutant embryos (Fischer et al., 2004; Kokubo et al., 
2005), and in Rbpsuh (Fischer et al., 2004), the primary transcriptional mediator of the 
Notch signaling, homozygous mutant embryos, suggesting that the Notch signaling 
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pathway plays an essential role in arterial differentiation, and is the upstream of ephrin-
B2 in arterial endothelial cells. 
Several studies in mice and zebrafish have suggested that VEGF induces the 
differentiation of arterial endothelial cells; zebrafish studies also demonstrate VEGF is 
upstream of the Notch signaling pathway in arterial differentiation.  Mice expressing only 
the VEGF120 or VEGF188 isoforms display defects in retinal arterial differentiation, and 
the VEGF188 mice have relatively normal veins but abnormal arteries (Stalmans et al., 
2002).  Transgenic mice overexpressing VEGF164 in the cardiac muscle under a myosin 
heavy chain (MHC) promoter show increased numbers of ephrin-B2+ capillaries at the 
expense of EphB4+ vessels in the heart, indicating that VEGF expression promotes the 
formation of additional arterial vessels (Visconti et al., 2002).  Moreover, VEGF from 
neurons and glia induces arterial differentiation in the vessels aligning with peripheral 
nerves in embryonic mouse limb skin (Mukouyama et al., 2002; Mukouyama et al., 2005).   
These studies in mice are consistent with the recent studies in zebrafish showing that 
VEGF is essential for arterial differentiation.  Reduction of VEGF activity using 
antisense morpholino oligonucleotides results in the loss of arterial marker expression in 
the dorsal aorta, the ectopic arterial expression of vein markers, and morphological 
defects in the aorta and cardinal vein; gain-of-function studies using VEGF mRNA leads 
to the ectopic expression of ephrin-B2 in the posterior cardinal vein (Lawson et al., 2002).  
The genetic interaction between VEGF and Notch signaling is further revealed by the 
results that VEGF mRNA injection into Notch signaling-deficient mindbomb mutant 
embryos does not display any induction of arterial markers in the trunk, suggesting 
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VEGF as the upstream of the Notch signaling pathway during arterial differentiation 
(Lawson et al., 2002). 
 
Lymphatic vessels 
When blood circulates through the vascular system, fluid and proteins leak out.  A 
network of lymphatic vessels collects this fluid from tissues and returns it to the vascular 
system.  In addition, lymphatic vessels serve an immune function by transporting white 
blood cells and antigen-presenting cells (Alitalo and Carmeliet, 2002).  However, the 
lymphatic vasculature remained poorly characterized until the recent identification of 
several lymphatic-specific genes.  Prox-1, a homeobox transcription factor, plays an 
essential role in specification of the fate of lymphatic endothelial cells (Wigle and Oliver, 
1999).  Prox-1 is initially expressed at E9.5 in a subpopulation of cardinal vein 
endothelial cells; these Prox-1+ venous endothelial cells subsequently bud, proliferate, 
and migrate to form the embryonic lymph sacs and lymphatic vascular network, 
supporting that lymphatic endothelial cells are originated from venous endothelial cells 
(Oliver, 2004; Wigle and Oliver, 1999).  Prox-1 homozygous mutant embryos display the 
absence of lymphatic vessels (Wigle et al., 2002; Wigle and Oliver, 1999), and Prox-1 
overexpression in cultured endothelial cells induces several lymphatic markers (Hong et 
al., 2002; Petrova et al., 2002), suggesting that Prox-1 is necessary and sufficient for the 
formation of lymphatic endothelial cells.  VEGF-C, a mitogen of lymphatic endothelial 
cells, is also essential for the formation of lymphatic vasculature, as revealed by the 
observation that targeted mutation of VEGF-C leads to arrested lymphatic development, 
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although Prox-1 expression is still initiated in the cardinal vein (Karkkainen et al., 2004).  
The signal that initiates Prox-1 expression in the cardinal vein remains elusive. 
Genetic ablation of Angiopoietin-2 (Ang2) results in chylous ascites, subcutaneous 
edema, and post-natal lethality within two weeks of birth, suggesting that Ang2 is 
essential for the development of lymphatic vasculature (Gale et al., 2002).  Interestingly, 
the lymphatic defects of Ang2 homozygous mutant mice were rescued by angiopoietin-1, 
suggesting that Ang2 is an agonist of the Tie2 receptor in the lymphatic vasculature, and 
stabilizes lymphatic vascular structure and integrity (Gale et al., 2002), whereas Ang2 is 
an antagonist of the Tie2 receptor in the blood vasculature (Maisonpierre et al., 1997).  
NP-2 appears to play an essential role in the development of small lymphatic vessels, as 
revealed by the results that NP-2 homozygous mutant mice display transient defects in 
the formation of small lymphatic vessels, while they do show normal development of 
large, collecting lymphatic vessels (Yuan et al., 2002).  Podoplanin, a transmembrane 
glycoprotein, homozygous mutant mice show defects in lymphatic vessel structure and 
function, and dilations of the cutaneous and submucosal intestinal lymphatic vasculature, 
suggesting that podoplanin is essential for lymphatic vasculature (Schacht et al., 2003).   
 
Heterogeneity of endothelial cells in embryos and adults 
Many molecular markers used to distinguish arteries, veins, and lymphatic vessels have 
been recently identified.  Their restrictive expression pattern in each type of vessel during 
development, suggests that there is homogeneity in the embryonic endothelial cells of 
these vessels.   However, it has been observed that adult endothelial cells are 
heterogeneous with respect to their cell surface glycoproteins and lectin binding patterns 
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and protein expression (Aird, 2003).  For example, en face preparations of adult mouse 
aorta have shown basal and lipopolysaccharide-induced expression of nuclear factor-κB 
in a subpopulation of endothelial cells that reside in regions with high probability for 
atherosclerotic lesion development (Hajra et al., 2000).  Are embryonic endothelial cells 
in a single vessel heterogeneous like adult endothelial cells?  A novel arterial-specific 
gene, Depp (decidual protein induced by progesterone), which I cloned and characterized, 
surprisingly, reveals the heterogeneity of arterial endothelial cells in a single vessel from 
the early stage of vascular development as well as the heterogeneity of adult endothelial 
cells in various tissues (as described in Chapter 2).  However, the significance of 
endothelial heterogeneity during development and in adulthood remains elusive. 
 
A marker of neovasculature in adults 
Neovascularization is essential for tumor growth, wound healing, and a variety of 
additional physiological and pathological processes.  Inhibition of new blood vessel 
formation in tumors impairs tumor growth, and causes necrosis or apoptosis of tumor 
cells (Hanahan and Folkman, 1996); inhibition of neovascularization in the skin 
significantly delays wound healing (Streit et al., 2000).  Such evidence has provoked 
numerous laboratories to search for molecules to block neovascularization.  More than 
300 potential angiogenesis inhibitors have been identified, of which approximately 80 
inhibitors are currently being tested in clinical trials for cancer treatment (Park et al., 
2004); monoclonal anti-VEGF antibodies inhibiting neovascularization have already been 
approved as a treatment of colorectal cancer (Hurwitz et al., 2004).   
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Tumor vasculature is molecularly different from normal vasculature.  Vascular 
endothelial growth factor receptors, integrins, extracellular matrix (ECM) proteins, and 
other genes have been reported as the molecular markers that distinguish tumor vessels 
from normal vessels (Ruoslahti, 2002).  Flk1 and Flt1 were induced in the endothelial 
cells of gliomas in the rat brain, and yet were not observed in the adult brain by 
radioactive in situ hybridization (Plate et al., 1993).  αvβ3 and αvβ5 integrins were up-
regulated in microvessels in human high-risk neuroblastomas (Erdreich-Epstein et al., 
2000), and  αvβ3 was induced in endothelial cells of human wound granulation tissues 
(Brooks et al., 1994).  Matrix metaloproteinase-9 was significantly up-regulated in 
endothelial cells of various tumors (Bergers et al., 2000; Hiratsuka et al., 2002).  Hela-
type caldesmon, an actomyosin-binding protein, was restrictively expressed in tumor 
vessels, and its expression was variable in the different tumor types (Zheng et al., 2005). 
More tumor-restricted endothelial markers have systematically been identified by 
comparing gene or protein expression profiles in endothelial cells derived from normal 
and tumor tissues (Madden et al., 2004; Oh et al., 2004; St Croix et al., 2000).  Eight new 
tumor-induced vascular proteins including annexin A1 were identified by comparing 
protein expression profiles in the endothelial surface of normal rat lung and solid tumors 
(Oh et al., 2004); nine new tumor endothelial markers (TEM1-9) were identified by 
comparing gene expression profiles in endothelial cells from normal and malignant 
human colorectal tissues (St Croix et al., 2000).  Annexin A1 and TEM1-9 were 
expressed in the endothelial cells of lung and colorectal tumors, but not in normal lung or 
colorectal tissues, respectively; furthermore, these genes were expressed in various 
tumors.  In vivo phage display also revealed more tumor-restricted endothelial markers 
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such as cell surface nucleoin, known as a shuttle molecule between the nucleus and the 
cell surface (Christian et al., 2003), and aminopeptidase N (Pasqualini et al., 2000).   
Despite the identification of numerous tumor-restricted endothelial markers, few of 
them have been utilized as definitive markers of neovasculature in adult tissues.  Some of 
the tumor-restricted endothelial markers such as Flk1 are substantially expressed in the 
endothelial cells of normal adult tissues (Madden et al., 2004).  Others are expressed in a 
subset of endothelial cells of tumor tissues (St Croix et al., 2000), or in specific tumor 
types (Zheng et al., 2005).  In addition, the expression of these markers was mainly 
examined by in situ hybridization or single-labeling immunohistochemistry, making it 
difficult to assume the percentage of the endothelial cells expressing these markers.  
Furthermore, that small regions of normal and tumor tissues were shown in figures to 
reveal tumor-specific endothelial expression of these markers makes it hard to evaluate 
these markers as pan-neovessel markers expressed in all newly formed vessels.  The 
detailed expression analysis of these markers is a prerequisite to clarify whether some of 
these markers could be used as a pan-neovessel marker. 
However, a novel endothelial-specific gene, D1.1, which I isolated and characterized, 
can be a pan-neovessel marker based on the following features.  First, D1.1 is barely or 
weakly expressed in microvessels of most adult tissues.  Second, D1.1 is highly 
expressed in the vessels of physiologically angiogenic tissues such as the ovary and the 
placenta.  Third, D1.1 is highly up-regulated in vessels during tumor angiogenesis and 
wound healing and in the corneal micropocket assay (as described in Chapter 3). 
 
Overview of the Thesis 
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The finding that ephrin-B2 is an arterial endothelial marker during early development led 
me to examine ephrin-B2 expression in adult tissues.  Ephrin-B2 is maintained in adult 
vasculature, suggesting that it is an arterial marker in adulthood as well.  Surprisingly, 
ephrin-B2 is expressed in the SMCs of arteries but not of veins, indicating that there is a 
molecular difference between arterial and venous SMCs as well as endothelial cells.  
Ephrin-B2 is also expressed in vessels during tumor angiogenesis and wound healing, 
suggesting that ephrin-B2 may play essential roles in adult angiogenesis.  These studies 
are described in Chapter 1. 
Ephrin-B2 was serendipitously characterized as an arterial marker; thus, I decided to 
do a systematic screen to isolate novel arterial- and venous-restricted genes from mouse 
embryos.  These genes would fill many gaps in our understanding of cardiovascular 
development.  It was challenging to purify sufficient numbers of arterial or venous 
endothelial cells from embryos for conventional, differential screens.  Therefore, I took 
an approach to employ differential screening of cDNA libraries constructed from single 
cells or small numbers of isolated arterial or venous endothelial cells.  I identified several 
arterial specific genes from this screen, and characterized two genes (Depp and D1.1) in 
detail by generating knockout mice.  Although both homozygous mutant mice appear 
phenotypically normal during development and in adulthood, both genes display 
interesting expression patterns.  Depp expression reveals the unexpected heterogeneity of 
arterial endothelial cells in the early stage of vascular development, and distinguishes 
Depp+ peripheral endothelial cells from Depp- endocardial cells of the heart.  All the 
studies related to the systemic screen and Depp are described in Chapter 2.   
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The other gene, D1.1, is homogeneously expressed in most endothelial cells of both 
arteries and veins during development; however, it is down-regulated in vessels of most 
adult tissues.  Surprisingly, D1.1 is up-regulated in most endothelial cells of adult 
neovasculature in tumors, during wound healing, and in the corneal micropocket assay, 
suggesting that D1.1 can be a useful pan-neovessel marker.  The detailed studies related 
to D1.1 are described in Chapter 3.   
These studies described in the first three chapters raise several interesting questions 
requiring subsequent investigation.  I describe in Chapter 4 these questions and future 
directions for further studies.   
The fact that Depp is expressed in peripheral endothelial cells but not in endocardial 
cells prompted me to generate Depp knockout mice by inserting EGFP-Cre cassette into 
the Depp locus.  EGFP-Cre cassette insertion permitted me to examine the detailed 
expression of Depp using GFP antibodies, and to utilize Depp mutant mice as a Cre 
deleter line to remove any loxP-flanked genes in peripheral endothelial cells but not in 
endocardial cells.  I used Depp mutant mice as a Cre deleter line to remove ephrin-B2 in 
peripheral endothelial cells but not in endocardial cells, in order to tackle an important 
issue about whether peripheral angiogenesis defects observed in ephrin-B2 conventional 
knockout mice reflect a local requirement for ephrin-B2 signaling, or rather may be 
secondary to the heart defects.  This study is described in the Appendix. 
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Chapter 1 
 
 
Expression of Ephrin-B2 Identifies a Stable Genetic Difference Between Arterial 
and Venous Vascular Smooth Muscle as Well as Endothelial Cells, and Marks 
Subsets of Microvessels at Sites of Adult Neovascularization 
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Chapter 2 
 
 
Isolation of Arterial-specific Genes by Subtractive Hybridization Reveals Molecular 
Heterogeneity among Arterial Endothelial Cells 
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ABSTRACT 
Arteries are distinguished from veins by differences in gene expression, as well as in their 
anatomy and physiology.  The characterization of arterial- and venous-specific genes may 
improve our understanding of cardiovascular development and disease.  Here we report 
the results of a subtractive hybridization screen for arterial-specific genes, and describe in 
detail the expression of a novel arterial-specific gene, Depp (decidual protein induced by 
progesterone), using a GFP-Cre knock-in that permits a comparison of both instantaneous 
and cumulative expression patterns in situ.  Several features of Depp expression are 
noteworthy.  First, Depp is expressed in endothelial cells of peripheral tissues, but not in 
atrial or ventricular endocardial cells of the heart.  Very few genes have been reported to 
discriminate between these two cell types, and therefore this specificity may be useful in 
generating conditional mutations in other genes implicated in cardiovascular 
development.  Second, Depp reveals an unexpected degree of molecular heterogeneity 
among arterial endothelial cells.  Third, Depp is up-regulated in subsets of endothelial 
cells, in settings of adult neo-vascularization, including tumor angiogenesis.  Taken 
together, these data reveal unanticipated temporal and spatial heterogeneity among 
arterial endothelial cells of various tissues and organs, raising new questions regarding 
the functional significance of this diversity. 
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INTRODUCTION 
Arteries are distinguished from veins by the direction of blood flow and by anatomical 
and functional differences.  The recent observation that several genes, including ephrin-
B2 (Adams et al., 1999; Gale et al., 2001; Shin et al., 2001; Wang et al., 1998), Dll4 
(Krebs et al., 2000; Shutter et al., 2000), activin receptor-like kinase 1 (Alk1) (Seki et al., 
2003), EPAS-1/hypoxia-inducible factor 2α (Tian et al., 1998; Tian et al., 1997), Hey1, 
and Hey2 (Nakagawa et al., 1999) are specifically expressed in arteries but not in veins, 
while EphB4 is enriched in veins (Gerety et al., 1999), indicates that there are multiple 
molecular differences between arteries and veins.  These molecular differences may 
cause or reflect functional, physiological, and anatomical differences between arteries 
and veins.   
Arterial- and venous-specific genes are also crucial for the proper development of the 
cardiovascular system.  Ephrin-B2 (Adams et al., 1999; Wang et al., 1998), EphB4 
(Gerety et al., 1999), Alk1 (Oh et al., 2000; Urness et al., 2000), and Dll4 homozygous 
mutants (Duarte et al., 2004; Gale et al., 2004) and Hey1/Hey2 double homozygous 
mutants (Fischer et al., 2004) have severe angiogenesis defects accompanied by heart 
defects.  EPAS-1 homozygous mutants have angiogenesis defects (Peng et al., 2000), 
albeit less severe than defects in ephrin-B2 or EphB4 mutants.  In addition to their role in 
development, recent data suggest that ephrin-B2 and EphB4 may play important roles in 
tumor angiogenesis (Martiny-Baron et al., 2004; Noren et al., 2004). 
The identification of additional arterial- and venous-specific genes should contribute 
to our understanding of cardiovascular development and disease.  However, most such 
genes discovered to date have been identified serendipitously; there have been relatively 
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few systematic attempts to identify novel arterial and venous-specific genes (Chi et al., 
2003).  Part of the reason for this is that it is very difficult to purify a sufficient number of 
arterial and venous endothelial cells for conventional subtractive hybridization or 
microarray screening, due to the absence of arterial- or venous-specific cell surface 
antibodies available for fluorescence-activated cell sorting (FACS).  This technical 
limitation prompted us to employ differential screening of cDNA libraries constructed 
from small numbers of isolated arterial or venous endothelial cells.  This screening 
method initially was developed to isolate pheromone receptor genes from single 
vomeronasal cells (Dulac and Axel, 1995; Pantages and Dulac, 2000), and has 
subsequently been applied to isolate novel genes from small numbers of cells from other 
tissues (Shimono and Behringer, 1999; Streit et al., 2000).   
We have cloned several arterial-specific genes using this approach, and have 
characterized one novel arterial-specific gene, Depp, by generating a targeted mutation in 
the Depp locus.  We introduced an EGFP-Cre fusion construct into this locus to visualize 
both the instantaneous expression of Depp, and to trace the lineage of Depp+ cells. 
Although homozygous Depp mutant mice do not show any obvious cardiovascular 
defects during development or in adulthood, the expression of Depp reveals an 
unexpected spatial and temporal heterogeneity of arterial endothelial cells.  Furthermore, 
Depp represents one of the few genes that differentiate peripheral vascular endothelial 
cells from endocardial cells.  The availability of a mouse line expressing Cre recombinase 
in such a pattern may permit a genetic dissection of the relative roles in the heart and 
peripheral vasculature, of genes important in cardiovascular development. 
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RESULTS 
Cloning of novel genes differentially expressed in arterial endothelial cells 
To find genes specifically expressed in arterial or venous endothelial cells, we dissected 
umbilical cords from wild-type E11 embryos, and separated the cords into umbilical 
arteries and veins under a dissecting microscope, based on their different morphology.  
These pooled arteries or veins were dissociated into single cells and incubated with two 
pan-endothelial antibodies, anti-PECAM-1-FITC and anti-FLK1-PE, and PECAM-1+/ 
FLK1+ endothelial cells were isolated by FACS (Fig. 1B, C).  All the isolated cells (2-
3,000 cells) were re-suspended in lysis buffer.  Duplicate aliquots of 10, 20, and 40 cell-
equivalent volumes from the re-suspended cells were taken and subjected to PCR 
amplification as described (Dulac and Axel, 1995).  The quality of the amplified cDNAs 
was evaluated by agarose gel electrophoresis (Fig. 1D).  The gel pattern of the cDNAs 
ranged from 300 bp to 1 kb without any distinct bands, implying unbiased amplification.  
The cDNAs were further evaluated by virtual Northern blotting, using eight different 
genes as probes: a house keeping gene, Tubulin; three pan-endothelial markers, Tie2, 
Flk1, and Flt1; three arterial endothelial specific markers, EPAS1, Dll4, and ephrin-B2; 
and a venous endothelial marker, EphB4 (Fig. 1E).  Tubulin and the three pan-endothelial 
genes were expressed at a relatively similar level between the umbilical arterial (UA) and 
umbilical venous (UV) cDNAs.  The arterial-specific genes were expressed at very low 
levels in UV, and strongly expressed in UA, as expected (Fig. 1E).  Based on this 
evaluation, a cDNA pair representing 40 cell-equivalents each of UA or UV endothelial 
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cells was chosen for further subtraction and differential screening (for details see 
Experimental Procedures).   
Virtual Northern blotting was performed for four candidate genes selected from the 
differential screen: Depp, connexin37 (Cx37), connexin40 (Cx40), and insulin-like 
growth factor binding protein-5 protease (IGFBP-5P).  This experiment confirmed their 
specific expression in UA or UV cDNAs (Fig. 1F).  These genes were then analyzed by 
in situ hybridization to verify their in vivo expression patterns.  The in situ hybridization 
data confirmed the arterial-specific expression of all four candidate genes at E10.5 (Fig. 
2G, H, I, J; arrows).  Depp was expressed in the dorsal aorta at E8.75 (Fig. 2B) but down-
regulated at E10.5 and E13.5.  However, at E10.5 Depp expression was strongly detected 
in vessels branching from the dorsal aorta (Fig. 2G, white arrow) as well as in small 
vessels (Fig. 2G, black arrowheads).  At E13.5, a subset of small vessels still expressed 
Depp (Fig. 2L, arrowheads).  Cx37 and Cx40 expression in the dorsal aorta persisted 
from E8.75 to E13.5 (Fig. 2C-M, D-N), the latest stage examined.  IGFBP-5P was not 
detectible in endothelial cells at E8.75 (Fig. 2E, arrow) but was expressed in the dorsal 
aorta at E10.5 and E13.5.  This gene was also expressed in the notochord during the 
interval examined (E8.75 to E13.5) (Fig. 2E-O, black arrowheads).   
 
Targeted mutagenesis of a novel arterial-specific gene, Depp 
Depp, decidual protein induced by progesterone, was cloned from human tissues and its 
sequence deposited into a public database in 1999, without further information.  We 
chose Depp for further analysis due to its unique expression pattern and sequence novelty.  
Sequences of rat, porcine, and bovine Depp orthologs have been deposited in the public 
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databases, but no apparent orthologs in zebrafish, fugu, or chicken have been reported.  In 
addition, there were no other Depp-related genes in the mouse or human genomes.  The 
N-terminal (about 59 amino acids) and C-terminal regions (about 21 amino acids) are 
highly conserved among the different mammalian species examined (Fig. 3A).  DEPP is 
predicted to be a soluble protein based on its amino acid sequence, and in vitro 
transfection experiment using a Depp-V5 epitope-tagged expression construct suggested 
that DEPP may be present in the cytoplasm (data not shown).  Depp has several putative 
consensus phosphorylation sites (Fig. 3A, circle, star, and square), but does not contain 
any conserved structural motifs.   
To assess the function of Depp in vivo, and to characterize its expression in more 
detail, we replaced the entire predicted coding region of the gene with an EGFP-Cre 
fusion gene, by homologous recombination in embryonic stem cells (Fig. 3B).  Germline 
chimeric mice were then generated from these ES cells by blastocyst injection.  This 
design permitted the “immediate” or “instantaneous” expression of Depp to be monitored 
by EGFP expression, and its cumulative or “historical” expression pattern to be examined 
by ß-galactosidase expression in DeppEGFP-Cre/+;Rosa26R mice.  
 
Depp is expressed in arterial endothelial cells and down-regulated in mature vessels 
during development. 
Our in situ hybridization data indicated that Depp is expressed in arterial endothelial cells 
of the dorsal aorta, but without a direct comparison to other arterial markers we were 
unable to address the question of its arterial specificity in smaller-diameter vessels.  To 
this end, we crossed DeppEGFPCre/+ mice to ephrinB2taulacZ/+ mice and examined 
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compound heterozygous embryos by double-labeling with antibodies to GFP and ß-
galactosidase.  At both E9.8 and E12.5, all GFP+ endothelial cells were ephrin-B2 + in the 
small vessels of limbs, as well as in dorsal aortic endothelial cells (Fig. 4C, F, I, L).  
(Note that the cytoplasmic tau-ß-galactosidase reporter used for ephrin-B2 and the 
nuclear EGFP-Cre reporter used for Depp exhibit distinct subcellular localizations, 
therefore arterial endothelial cells often appear as green nuclei surrounded by red 
cytoplasm; Fig. 4I, L.)  At no stage examined was Depp expression detected in veins (Fig. 
4A, D, M; open arrowheads).  These data confirm the pan-arterial specificity of Depp 
expression within the peripheral vasculature.  The cellular resolution afforded by 
expression of the EGFP reporter revealed, unexpectedly, that at E9.8 Depp is expressed 
in only a subset of endothelial cells within the dorsal aorta (Fig. 4A, M, arrows).  By 
E12.5, Depp was expressed in very few dorsal aortic endothelial cells, while it was 
expressed by a subset of endothelial cells branching from the dorsal aorta (Fig. 4D, arrow 
vs filled arrowhead).  These data suggested that Depp is transiently expressed by subsets 
of developing arterial endothelial cells, in both the dorsal aorta and peripheral vasculature.   
The heterogeneous expression of Depp-EGFP in dorsal aortic endothelial cells at E9.8 
raised the question of whether the EGFP- cells represent a subpopulation that never 
expresses the gene, or rather cells that down-regulated expression prior to the stage 
analyzed.  To distinguish these possibilities, we crossed DeppEGFPCre/+ mice to Rosa26R 
Cre reporter mice.   Double-labeling with antibodies to GFP and ß-galactosidase on 
sections of E9.8 and E12.5 DeppEGFP-Cre/+;Rosa26R embryos indicated that most 
endothelial cells of E9.8 and E12.5 dorsal aorta expressed ß-galactosidase (Fig. 4N, O, Q, 
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R).  These data suggest that most GFP- endothelial cells in E9.8 dorsal aorta had 
transiently expressed Depp earlier during development.   
In the peripheral vasculature, Depp was maintained in limb vessels until at least E12.5, 
a time when Depp was barely expressed in dorsal aortic endothelial cells (Fig. 4D, arrow; 
G, J).  By adulthood, however, Depp was down-regulated in most small diameter vessels 
of the limb (see below and data not shown).  The transient nature of Depp expression 
raised the question of whether it was correlated with proliferation.  Double-labeling with 
antibodies to GFP and phospho-histone3 (Fig. 8G, I; red vs green) or Ki67 (data not 
shown) indicated, however, that there was no correlation between proliferation and Depp 
expression.   
 
Heterogeneous expression of Depp in adult vasculature 
We next examined the expression of Depp in adult tissues, by performing double labeling 
with antibodies to GFP and PECAM-1.  Depp was heterogeneously expressed in a subset 
of adult vessels, but this varied in different organs.  For example, small-diameter vessels 
in the fat around the dorsal aorta, the heart, and the neocortex (Fig. 5A-F) contain 
abundant subsets of Depp+ endothelial cells.  The vasculature of these tissues contains 
more Depp-EGFP+ endothelial cells than does that of some other tissues, such as kidney 
or liver (Fig. 5G, O); furthermore, the neocortex contains more Depp+ endothelial cells 
than other regions of the brain (data not shown).  Depp is also expressed in lung epithelial 
cells, pancreatic islet cells, and liver hepatocytes as well as in a subset of endothelial cells 
of these organs (Fig. 5K-P, arrowheads and arrows).  Depp expression was restricted to 
arterial endothelial cells in P5 retina (Fig. 5Q, arrow); its expression in most other adult 
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organs was predominantly (but not absolutely) restricted to ephrin-B2+ arterial 
endothelial cells (data not shown). 
Within each tissue, Depp expression in the arterial vasculature was inhomogeneous.  
For example, in the kidney Depp is mostly restricted to the endothelial cells of the 
glomeruli (Fig. 5G, H; arrow).  In the uterus of a pregnant female bearing E11 embryos, 
Depp was expressed in a small subset of endothelial cells (Fig. 5I, arrow); however, the 
placenta from the same female did not have any Depp+ endothelial cells (data not shown).  
Depp was also expressed in a subset of uterine epithelial cells of pregnant females (Fig. 
5I, arrowhead), but not in the uterus of a non-pregnant female (data not shown).  This 
observation is consistent with the original identification of Depp as a decidual protein.  
We attempted to determine whether Depp expression could be induced in this tissue by 
progesterone administration, but no consistent results were obtained (data not shown). 
We also examined expression of Depp in various settings of adult neovascularization.  
Depp was expressed in a subset of vessels in tumors and wounded skin (Fig. 5S-X).  In 
some cases, the expression of Depp in such neo-vessels appeared greater than in 
neighboring, static vessels (Fig. 5W, X and data not shown).  Examination of ß-
galactosidase expression in such vessels in DeppEGFPCre/+; Rosa26R mice indicated that 
many more cells were lacZ+ than were GFP+ (data not shown).  Whether the high level of 
Depp-Cre mediated recombination in such neo-vessels represents a transient induction of 
the gene during neovascularization, or rather the recruitment of endothelial cells that once 
expressed Depp during development, cannot presently be distinguished. 
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Depp is not expressed in endocardial cells of atria or ventricles, but is expressed in a 
subset of outflow tract endocardial cells. 
The fact that most endothelial-specific genes, including ephrin-B2 (Wang et al., 1998), 
EphB4 (Gerety et al., 1999), Flk1 (Shalaby et al., 1995), Flt1(Fong et al., 1995) , Tie1 
and Tie2 (Sato et al., 1993), VE-cadherin, CD34, PECAM-1, and TAL1 (Drake and 
Fleming, 2000), are also expressed in endocardial cells complicates the interpretation of 
cardiovascular phenotypes in mice bearing mutations in these genes.  Therefore, we 
investigated whether Depp is, similarly, also expressed in endocardial cells.   
Strikingly, Depp-EGFP was not expressed in endocardial cells of the atria or 
ventricles (Fig. 6A, B, D, E), whereas it was expressed in a subset of myocardial cells of 
the atrio-ventricular and bulbo-ventricular canals (Fig. 6A, C; arrow and arrowheads).  
Furthermore, Depp-Cre mediated lineage tracing experiments indicated that Depp is not 
expressed in progenitors of atrial or ventricular endocardial cells (Fig. 6K, N).  
Recombination (ß-gal expression) without GFP expression was detected in the 
trabeculated region of a ventricle (Fig. 6J, arrow and black arrowhead).  The fact that 
myocardial precursors migrate from pharyngeal arches through outflow tracts to 
ventricles and further to atria (Cai et al., 2003; Kelly et al., 2001) may explain this 
observation; alternatively Depp may be transiently expressed in precursors of these 
myocardial cells.  Further analysis of Depp expression in other cardiac regions revealed 
that Depp is also expressed in a subset of endocardial and myocardial cells of the outflow 
tracts (OFT; Fig. 6G, arrow vs arrowhead).  This OFT expression was detected by both 
expression of GFP, and of the Cre-dependent reporter (Fig. 6P, arrow). 
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Depp is not required for vessel development or maintenance. 
The unique cardiovascular expression pattern of Depp prompted us to examine the 
cardiovascular development of Depp homozygous mutant embryos.  Whole-mount 
staining with anti-PECAM-1 antibodies revealed that there were no obvious differences 
in vessel development or patterning between E9.5 wild-type and homozygous mutant 
embryos (Fig. 7A-D), or yolk sacs (Fig. 7E, F).  Double-labeling with antibodies to α-
SMA (Gothert et al.) and PECAM-1 (red) revealed no obvious differences between wild-
type and homozygous mutant hearts in terms of ventricular trabeculation or atrial and 
ventricular morphology (Fig. 7G, H) 
Although Depp is down-regulated in mature vessels by E10, its expression persists in 
small vessels in later stage embryos.  Therefore, we examined the vascular morphology 
of wild-type and the homozygous mutant embryos at E15.5.  Whole-mount staining with 
anti-PECAM-1 antibodies revealed no clear differences between E15.5 wild-type and 
homozygous mutant forelimb skin (Fig. 7I, J), stomach (Fig. 7K, L), intestine (Fig. 7M, 
N), and kidney (data not shown).  Because retinal vessel development occurs after birth 
(Fruttiger, 2002) and is sensitive to angiogenic factors such as VEGF and angiopoietin-1 
(Stalmans et al., 2002; Uemura et al., 2002), we also examined retina vasculature by 
double-labeling with antibodies to α-SMA and PECAM-1.  However, there was no 
obvious difference between P5 wild-type and the homozygous mutant retinae (Fig. 7O, P).  
In addition, Depp homozygous mutant mice developed normally without any apparent 
physiological or developmental defects, and are fertile in both a 129/c57Bl6 mixed 
background and pure 129 background.   
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Depp is expressed in a subset of vessels in tumors and wounded skin; therefore, we 
asked whether pathological angiogenesis in tumors and wounded skin is affected in 
homozygous mutant mice, by implanting Lewis lung carcinoma cells subcutaneously or 
by making skin wounds in the back of the mutant mice.  The tumor size and extent of 
vascularization, and the wound healing and skin vascularization, in the homozygous 
mutant mice were similar to those in heterozygous and wild-type mice (data not shown). 
 
Arterial endothelial differentiation, proliferation, and survival are normal in Depp 
homozygous mutant embryos. 
The arterial-specific expression of Depp prompted us to examine arterial differentiation 
in Depp homozygous mutant embryos.  To address this, we intercrossed DeppEGFP-Cre/+ 
with ephrin-B2lacZ/+ mice.  Depp+/-;ephrin-B2lacZ/+ and Depp-/-;ephrin-B2lacZ/+ embryos at 
E9.5 were processed for staining with anti-β-galactosidase antibodies to reveal ephrin-B2 
expression.  Ephrin-B2 was expressed in the homozygous embryos similarly as in the 
heterozygous embryos (Fig. 8A, B).  Another arterial-endothelial marker, Cx40, was also 
expressed in the homozygous mutant (Fig. 8C, D); smooth muscle cells were normally 
recruited to the homozygous mutant dorsal aorta (Fig. 8E, F).  We also examined 
proliferation (Fig. 8G-J) and apoptosis (Fig. 8K-L) in the mutant embryos, but there was 
no significant difference between the homozygous and heterozygous embryos at E9.5.  
These data suggest that arterial differentiation is normal in Depp-/- embryos, and that 
there are no genetic interactions between ephrin-B2 and Depp affecting arterial 
differentiation. 
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To more systematically examine the effect of the Depp mutation on endothelial cells, 
we analyzed the gene expression profiles of Depp+ endothelial cells isolated by FACS 
from homozygous and heterozygous mutant embryos at E10.  GFP+/PECAM-1+/FLK1+ 
endothelial cells were isolated, and their cDNAs amplified and subjected to microarray 
analysis.  There were no significant differences in the expression level of known 
endothelial genes between the homozygous and heterozygous Depp+ endothelial cells 
(data not shown).  A small subset of genes exhibited significant differences in their 
expression levels, but in situ hybridization for these genes failed to confirm these 
differences when comparing homozygous and heterozygous embryos.  These data 
suggest that the differentiation of Depp+ endothelial cells is relatively normal in Depp 
homozygous mutant embryos. 
 
DISCUSSION 
In this study, we undertook a systematic approach to identify arterial-specific genes, 
using primary endothelial cells from umbilical vessels of E11 embryos.  We have 
described in detail the expression pattern of a novel arterial-specific gene, Depp, using a 
genetic approach that permits visualization of both instantaneous and cumulative 
expression in situ.  The expression of Depp revealed several unexpected features of 
vascular endothelial cell heterogeneity.  First, Depp is expressed in endothelial cells of 
peripheral tissues, but not in atrial or ventricular endocardial cells of the heart, identifying 
a molecular distinction between these two endothelial cell sub-types.  Second, Depp 
revealed that arterial endothelial cells are molecularly heterogeneous.  Finally, Depp is 
induced in subsets of endothelial cells, in some settings of adult neo-vascularization, 
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indicating heterogeneity within this population as well.  The biological significance of the 
molecular heterogeneity revealed by Depp expression is not yet clear; nevertheless, it 
points to previously unsuspected diversity and complexity within arterial endothelial cell 
populations. 
 
A systematic screen to identify novel arterial-specific genes 
An important feature of our screen was the use of freshly isolated, rather than cultured, 
arterial or venous endothelial cells.  While cultured cells may be a more convenient 
source of material, the arterial or venous identity of the endothelial cells may change in 
vitro.  For example, cultured human umbilical vein endothelial cells (HUVEC) express an 
arterial marker, ephrin-B2 (Kim et al., 2002).  In addition, venous endothelial cells 
express ephrin-B2 in response to VEGF in vitro (Y. Mukouyama and D. J. Anderson, 
personal communication), whereas they do not express ephrin-B2 in vivo.  These data 
suggest that arterio-venous identity is plastic in vitro, and underscore the importance of 
using freshly isolated, uncultured cells to screen for markers of such identity. 
In a previous study, the expression profiles of 53 different populations of cultured 
endothelial cells were investigated using DNA microarrays.  The comparisons performed 
included large vessel-derived endothelial cells vs. microvascular endothelial cells, and 
artery-derived endothelial cells vs. vein-derived endothelial cells (Chi et al., 2003).  The 
study reported 59 putative artery-specific genes, and confirmed the arterial-specific 
expression of three of these genes (Hey2, C17, and CD44), using cultured endothelial 
cells, rather than in situ hybridization to embryonic tissue as we have done here.  In 
contrast to the present work, this previous study did not identify Cx37, Cx40, Depp, or 
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IGFBP-5P as artery-specific genes.  It is not clear whether these genes were not present 
on the 43K cDNA chips used in the earlier analysis, or whether the arterial-specific 
expression of these genes was lost under the culture conditions used to prepare the cells 
for microarray analysis.   
 
Depp is expressed in peripheral endothelial cells, but not in atrial or ventricular 
endocardial cells. 
We focused on Depp in part because our initial in situ hybridization analysis indicated 
that it is expressed in arterial endothelial cells of peripheral blood vessels, but not in atrial 
or ventricular endocardial cells of the heart.  By contrast, most endothelial-specific genes 
are expressed in both endothelial and endocardial cells.  This differential expression of 
Depp was confirmed using the GFP reporter.  Furthermore, the cumulative expression 
pattern of Depp, visualized using the Depp-Cre line, revealed that transient expression of 
Depp does not occur in atrial or ventricular endocardial cells at any time up to the stages 
analyzed.  This selectivity of Depp-Cre recombination may be useful in generating 
conditional mutations in other genes implicated in cardiovascular development, which are 
expressed in endothelial/endocardial but not in myocardial cells, to resolve the question 
of whether peripheral angiogenesis defects observed in conventional knockouts are 
primary, or secondary to cardiac defects.  For example, we have used Depp-Cre mice to 
generate peripheral endothelial-specific knockouts of ephrin-B2 (Gerety and Anderson, 
2002; Wang et al., 1998), and observe vascular phenotypes in mutant embryos (D.S. and 
D.J.A., unpublished data).  We note, however, that Depp is also expressed in endothelial 
cells of the cardiac outflow tract.  Like Depp, Connexin40, a gap junction gene, is also 
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expressed in arterial endothelial cells and in OFT endocardial cells, but not in atrial or 
ventricular endocardial cell (Delorme et al., 1997).  However, Cx40-Cre mice have not 
yet been described, so it is not clear whether this gene may be transiently expressed 
during endocardial development. 
 
Molecular heterogeneity among arterial endothelial cells 
The heterogeneous expression of Depp in the embryonic dorsal aorta indicates that 
neighboring endothelial cells within this vessel can be molecularly distinct.  Definitive 
hematopoiesis takes place in the ventrally positioned endothelial cells of the dorsa aorta 
within the aorta-gonad-mesonephros region from E10 to E12 (de Bruijn et al., 2000; 
Medvinsky and Dzierzak, 1996).  AML1 is expressed in these ventrally positioned 
hemogenic endothelial cells, but not in dorsally positioned endothelial cells, and is 
required for the formation of intra-aortic hematopoietic clusters from the hemogenic 
endothelium (North et al., 1999).  By contrast, Depp is not differentially expressed 
between dorsally and ventrally positioned, or between left and right, endothelial cells of 
the dorsal aorta.  Rather, it is expressed in scattered endothelial cells distributed evenly 
throughout the dorso-ventral axis of the vessel wall, at E9.8 (Fig. 4A, M).  A similarly 
scattered, heterogeneous expression pattern of Alk1 in the dorsal aorta at E15.5 was 
recently demonstrated by X-gal staining in Alk1LacZ/+ mice (Seki et al., 2003); however, 
Alk1 seems expressed in most endothelial cells of the dorsal aorta at E11.5 (Seki et al., 
2003).  Therefore, Depp expression in the dorsal aorta at E9.8 uniquely reveals the 
heterogeneity of early embryonic arterial endothelial cells within a single vessel.  
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Heterogeneity within adult vessels has previously been reported using lectins and other 
markers (Aird, 2003; Caprioli et al., 2004). 
The heterogeneous expression of Depp suggested that it might be correlated with 
proliferation.  However, immunohistochemical analysis using anti-phospho-histone3 and 
anti-GFP revealed no correlation between Depp expression and proliferation.  In addition, 
TUNEL assays showed no correlation between Depp expression and cell death.  The 
functional significance of the heterogeneity revealed by Depp expression, therefore, 
remains to be elucidated. 
 
Depp is induced in subsets of vessels in neo-angiogenic settings 
Our analysis revealed that Depp is expressed in at least two settings of neo-angiogenesis:  
tumor vascularization and wound healing.  Depp is also expressed in subsets of 
endothelial cells in a corneal micropocket assay (data not shown).  Interestingly, a direct 
comparison of GFP with ß-galactosidase expression in such neo-vessels, in DeppEGFP-
Cre/+; Rosa26R mice, indicated that many more endothelial cells were lacZ+ than were 
GFP+ (data not shown).  On the one hand, this difference could reflect a transient 
induction of Depp expression during adult neo-angiogenesis, similar to its dynamic 
regulation during embryonic development.  On the other hand, the difference could 
reflect the recruitment, to new adult vessels, of endothelial cells that transiently expressed 
Depp during embryonic development.  Inducible control of Depp-Cre expression after 
tumor implantation or wounding will be required to distinguish between these 
possibilities.  In both cases, however, the GFP reporter indicates that persistent 
expression or induction of Depp occurs in some endothelial cells of adult neo-vessels.  If 
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Depp is indeed transiently expressed in such settings, then the Depp promoter could be 
useful to target other genetic modifications to sites of adult neo-angiogenesis. 
 
Depp is not essential for vessel development or maintenance. 
Despite its novel expression pattern, Depp homozygous mutants did not show any 
detectable phenotypic defects during development or in adulthood.  This is surprising, as 
there are no other Depp-related genes in the mouse genome.  Nevertheless, functionally 
redundant genes, whose amino acid sequences are not homologous to that of DEPP, 
might compensate for the lack of Depp in the homozygous mutants.  The fact that DEPP 
is a cytoplasmic protein (data not shown), and has several putative consensus serine-, 
threonine-, and tyrosine-phosphorylation sites, suggests that it may function in a signal 
transduction pathway.  If so, then this pathway might be compensated by other genes in 
the same pathway, or by other pathways, in Depp homozygous mutant mice.  
Alternatively, DEPP might be important only under special conditions of physiologic 
responses to stress, injury or infection, which we have not yet systematically investigated. 
Recently, additional human and mouse Depp sequences have been deposited into the 
public sequence databases with new names: Fig (fasting induced gene) and Fseg (fat-
specific expressed gene).  In addition to its original name, Depp (decidual protein 
induced by progesterone), the new name, Fig, suggests that Depp expression might be 
dynamically regulated by extra-cellular signals, or physiological homeostatic 
mechanisms.  The fact that Depp is expressed in uterine epithelia of pregnant females 
(Fig. 5I), but not of non-pregnant females, further supports the idea that Depp expression 
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is dynamically regulated by extra-cellular signals.  The nature of these signals, and the 
significance of Depp regulation, remains to be determined. 
 
Molecular logic of arterio-venous identity specification 
Our screen was designed, in principle, to detect venous-specific as well as arterial-
specific genes.  However, despite analyzing the same number of E. coli colonies from the 
subtracted umbilical venous cDNA library as we did from the arterial cDNA library, we 
did not identify any venous-specific genes.  Why did we fail to find a single venous-
specific gene?  EphB4 is the only known venous endothelial-specific marker in mice 
(Gerety et al., 1999).  Nevertheless, virtual Northern blots probed by EphB4 (Fig. 1E) 
revealed a strong EphB4 signal even in the arterial cDNA sample.  Consistent with this, 
immunofluorescent staining of EphB4LacZ/+ embryos with antibodies to ß-galactosidase 
revealed EphB4 expression in arterial endothelial cells, albeit weaker than in venous 
endothelial cells (Shin et al., 2001).  These data indicate that the differential expression of 
EphB4 between arterial and venous endothelial cells is quantitative, rather than all-or-
none.  By contrast, expression of arterial markers such as ephrinB2 is virtually 
undetectable in venous endothelial cells, by a number of methods.  If this fundamental 
quantitative vs. qualitative difference in venous- vs. arterial-specific genes, respectively, 
is general, then the screening method used here may have systematically selected against 
the former category of genes, due to the PCR-based cDNA amplification step. 
It is interesting to speculate why venous-enriched genes are still expressed at low 
levels in arterial endothelial cells, whereas arterial-specific genes are all-or-none.  In 
zebrafish and mouse, VEGF and Notch signaling specifies arterial endothelial cells by 
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inducing arterial markers and repressing venous markers (Lawson et al., 2001; Lawson et 
al., 2002; Mukouyama et al., 2005).  Mouse Flt4, a receptor tyrosine kinase, is initially 
expressed in both arterial and venous endothelial cells during early development, but 
becomes restricted to venous endothelial cells at E11.5, and then later to lymphatic 
endothelial cells (Dumont et al., 1998; Kaipainen et al., 1995).  These and other data 
suggest that arterial specification might require the induction of a battery of arterial-
specific genes and the repression of venous-specific genes, whereas venous specification 
might simply require the maintenance and/or up-regulation of venous-specific genes.  
Such a mechanism would be consistent with the view of the venous fate as a “default” 
fate for the artery vs. vein decision (Sato, 2003; Thurston and Yancopoulos, 2001).  This 
view interprets the persistent expression of venous-enriched genes in arterial endothelial 
cells as a consequence of the developmental history of arterial fate-specification.  
Whether this persistent expression has any functional utility, for example with respect to 
phenotypic plasticity, is an interesting question for future investigation. 
 
EXPERIMENTAL PROCEDURES 
PCR-amplification, subtraction, and differential screening 
Umbilical cords from wild-type E11 embryos were dissected in HBSS, and separated into 
umbilical arteries (UA) and veins (UV) under a dissecting microscope based on their 
different morphology: the arterial vessels are thinner than the venous vessels and 
bifurcate close to the embryo, while the venous vessels are single tubes.  Each sample of 
pooled vessels as dissociated into single cells by digestion with type 1 collagenase 
(Worthington) and deoxyribonuclease type 1 (DNase 1; Sigma), labeled with FITC-
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conjugated anti-PECAM-1 antibody (BD Pharmingen) and PE-conjugated anti-FLK1 
antibody (BD Pharmingen), and PECAM-1+/ FLK1+ endothelial cells were isolated by 
FACS (Mukouyama et al., 2002).  All sorts and analyses were performed on a FACS 
Vantage dual laser flow cytometer (BD Biosciences).  
The isolated cells were re-suspended in 20 µl of lysis buffer, and aliquots containing 
10-, 20-, or 40-cell equivalents were taken and subjected to single-cell based PCR 
amplification, essentially as described (Dulac and Axel, 1995).  Each 5 µg of the 
amplified cDNAs were loaded on 1.5% agarose gels for electrophoresis to check the 
quality of the cDNAs, and transferred into a Hybond-N+ membrane (Amersham) 
followed by virtual Northern blotting using 3’-biased cDNA probes against a house 
keeping gene, Tubulin; three pan-endothelial markers, Tie2, Flk1, and Flt1; three arterial 
endothelial specific markers, EPAS1, Dll4, and ephrin-B2; and a venous endothelial 
marker, EphB4.  Based on these data, a single pair of 40-cell UA and UV cDNAs as 
selected for subtraction, which was performed essentially as described (Shimono and 
Behringer, 2000).  Briefly, the cDNAs were digested with EcoRI, and the gaps created by 
EcoRI digestion were filled using the Klenow fragment of DNA polymerase I.  Then, the 
cDNAs were loaded on 1.5% agarose gel to isolate cDNAs between 150 bp and 1.5 kb; 
each 150 ng of the gel-purified cDNAs as cut by AluI, AluI and RsaI restriction enzyme, 
or was left un-cut.  These three cDNAs were pooled, ligated with phosphorylated linkers 
containing EcoRI sites, and amplified by PCR with a primer containing sequences 
complementary to the phosphorylated linker.  For subtraction, the driver cDNAs were 
photobiotinylated, hybridized with unbiotinylated tester cDNAs, and removed by 
Streptavidin and phenol-chloroform extraction.  This was followed by re-amplification of 
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the subtracted cDNAs using the same primer as used for phophorylated linker preparation.  
This subtraction step was repeated twice.  The subtracted cDNAs were subjected to 
differential screening using the PCR-Select Differential Screening Kit (Clontech) with 
modifications.  Briefly, the subtracted cDNAs were ligated with pGEM-T easy vector 
(Promega), about 800 E. coli colonies were picked and cultured, the cDNA in each E. 
coli was amplified by PCR with a primer (5’-
TCCAGGCCGCTCTGGACAAAATATGA-3’) and transferred into Hybond-N+ 
membranes in quadruplicate, and Southern blotting was performed using 4 different 
probes, representing unsubtracted umbilical arterial and venous cDNAs, and subtracted 
umbilical arterial and venous cDNAs.  cDNAs showing differential signal intensities 
were selected for virtual Northern blotting to check the expression levels of the selected 
genes in the unsubtracted umbilical arterial and venous cDNAs (Fig. 1F).  Those genes 
exhibiting differential expression between the unsubtracted arterial and venous cDNAs 
were further examined for in situ hybridization, to check their in vivo expression patterns 
(Fig. 2). 
 
Generation of Depp mutant allele 
The arms of the Depp targeting construct were subcloned from a 129/SvJ genomic DNA 
BAC clone (Roswell Park Institute).  An EGFP-Cre fusion construct containing a poly A 
signal from pBS592 (Le et al., 1999) was inserted into the start codon of Depp, and an 
FRT-flanked PGK-neo selection cassette (Meyers et al., 1998) was inserted into the stop 
codon of Depp.  Then the 2.86 kb right arm fused with the FRT-flanked PGK-neo 
cassette was inserted downstream of EGFP-Cre, following the 2.8 kb left arm.  In this 
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way, the entire coding region of Depp was deleted in this targeting construct.  
Homologous recombination was performed in mouse CJ7 embryonic stem (ES) cells 
following standard procedures. Correctly targeted ES cell clones were identified by 
Southern blot hybridization using a probe that flanked the 3′ arm of the targeting 
construct, and an internal probe in the 5’ arm. Chimeric mice were produced by 
blastocyst injection and were mated to C57Bl/6 mice to establish lines.  The Depp allele 
was deposited as MGI:3526084.  The FRT- flanked PGK-neo selection cassette was 
removed by crossing with human ß-actin FLPe deleter mice (Jackson).  The deletion of 
the selection cassette significantly decreased Cre activity without noticeably altering its 
specificity; therefore, mutant mice retaining the selection cassette were used in this paper.   
 
Genotyping 
The genotyping of Depp mutant mice was performed by PCR using two primer sets 
detecting the wild-type and the mutant allele: WT1 (5’-
CTACGTCAGGTGTATCTGTCAGCT-3’) and WT2 (5’-
AAGAACCAGTCCTGTTGGGTCGAC-3’) primers, 269 bp PCR products; Cre1 (5'-
GTTCGCAAGAACCTGATGGACA-3') and Cre2 (5'-
CTAGAGCCTGTTTTGCACGTTC-3') primers, 319 bp PCR products.   
For Depp;ephrinB2 and Depp;Rosa26R double mutant mice, the LacZ primers, LacZ1 
(5'-CGCCCGTTGCACCACAGATG-3') and LacZ2 (5'-
CCAGCTGGCGTAATAGCGAAG-3') producing 370 bp PCR products, were used with 
the above WT and Cre primers. 
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In situ hybridization 
In situ hybridization was carried out essentially as described (Wang et al., 1998).  
Embryos were cryosectioned at 20 µm, and adjacent sections were hybridized with cRNA 
probes against Flk1 (1035 bp), Depp (800 bp), Cx37 (978 bp), Cx40 (1000 bp), and 
IGFBP- 5P (897 bp). 
 
Immunohistochemistry 
Embryos younger than E10 were first fixed for 1-2 hours in 4% paraformaldehyde/PBS at 
4°C, washed with PBS, sunk in 15% sucrose/PBS, embedded in 15% sucrose and 7.5% 
gelatin in PBS, and 20 µm sections were collected on a cryostat.  Older embryos were 
fixed for 2-4 hours, sunk in 30% sucrose/PBS, frozen in OCT medium, and 20 µm 
sections were collected on a cryostat.  Adult organs were fixed for 6-8 hours, washed with 
PBS, cryoprotected in 30% sucrose/PBS overnight at 4°C, frozen in OCT medium, and 
20 µm sections were collected on a cryostat.  Staining was performed using anti-PECAM-
1 antibody (Pharmingen, 1:300 overnight at 4°C), rabbit anti-GFP antibody (Molecular 
Probes, 1:1000, overnight at 4°C), chicken anti-GFP antibody (Aves Labs, 1:1000, 
overnight at 4°C), anti-ß-galactosidase antibody (5-prime 3-prime, 1:1000, overnight at 
4°C), anti-CX40 antibody (Alpha Diagnostic International, 1:300, overnight at 4°C), Cy3-
conjugated anti-α-SMA antibody (Sigma, 1:500, 40 minutes at room temperature), anti-
NF-ATc1 antibody (gift from Dr. G. Crabtree, Standford U., 7A6, 1:300, 1 hour at room 
temperature), and anti-phospho-histone3 antibody (Sigma , 1:000, overnight at 4°C).  For 
immunofluorescent detection; FITC-, Cy3-, Cy5-, Alexa-488-, or Alexa-568-conjugated 
secondary antibodies (Jackson, 1:300; Molecular Probes, 1:250, 40 minutes at room 
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temperature) were used. TUNEL labeling was performed according to the manufacturer's 
protocol (In Situ Cell Death Detection, Roche).  All confocal microscopy was carried out 
on a Leica SPP confocal (Leica).   
For whole-mount staining, embryos and organs were first fixed for 1-2 hours in 4% 
paraformaldehyde/PBS at 4°C, washed with PBS, and dehydrated in 100% methanol at -
20°C.  Staining was performed with anti-PECAM1 antibody (Pharmingen, 1:200 
overnight at 4°C), rabbit anti-GFP antibody (Molecular Probes, 1:1000, overnight at 4°C), 
and Cy3-conjugated anti-α-SMA antibody (Sigma, 1:500, 1 hour at room temperature); 
either HRP-conjugated secondary antibodies (Jackson, 1:300, overnight at 4°C) or 
secondary antibodies conjugated to Cy5- or Alexa-488 (Jackson, 1:300, and Molecular 
Probes 1:250, 1 hour at room temperature) were used. 
 
Pathological studies: tumors, cutaneous wounding, and corneal micropocket assay 
All procedures were carried out under protocols reviewed and approved by the IACUC 
(Institute Animal Care and Use Committee).  Mice were implanted subcutaneously with 
200 µl of 2 x 106 Lewis lung carcinoma cells (LLC), and sacrificed between 13 to 16 
days postimplantation when the diameter of the tumors reached 1.5 cm.  The tumors were 
dissected, weighed, fixed for 6-8 hours in 4% paraformaldehyde/PBS at 4°C, 
cryoprotected overnight in 30% sucrose/PBS at 4°C, frozen in OCT medium, and 20 µm 
sections were collected on a cryostat.  Mice were also implanted intraperitoneally with 
200 µl of 2 x 106 B16F10 melanoma cells, and sacrificed between 12 to 16 days 
postimplantation when they were lethargic.  The tumors close to the pancreas and spleen 
were dissected, and processed for immunohistochemistry like LLC tumors. 
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Full-thickness cutaneous wounds were made on the back skin of mice using a sterile, 
disposable 6-mm dermal biopsy punch (Miltex).  Animals were sacrificed and the tissue 
was examined 7 days afterward. 
The mouse corneal micropocket assay was performed as described previously 
(Kenyon et al., 1996) using hydron-coated sucralfate pellets containing 100 ng of bFGF 
(PeproTech).  
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FIGURE LEGENDS 
Fig. 1. Screening procedure to identify arterial-specific genes. Umbilical vessels of wild-
type E11 embryos were dissected (A, dotted lines), separated into arteries (A, red) and 
veins (A, blue), and incubated with anti-FLK1-PE and anti-PECAM-1-FITC antibodies.  
Modified from Carlson (Carlson, 1981).  Double-positive endothelial cells from each 
sample (arterial or venous) were sorted by FACS (B, C).  Electrophoresis of 5 µg of 
amplified cDNAs on 1.5% agarose gel reveals similar smear patterns among cDNAs 
amplified from 10-, 20-, and 40-cell equivalents (D).  Amplified cDNAs representing 40-
cell equivalents of umbilical arteries (UA, red) or veins (UV, blue) were selected for 
further analysis based on the amplification profiles of 8 marker genes: a house keeping 
gene, Tubulin; three pan-endothelial genes, Tie2, Flk1, and Flt1; three arterial-specific 
genes, EPAS-1, Dll4, and ephrin-B2; and a venous-restricted gene, EphB4 (E).  Note that 
arterial-specific genes are highly expressed in UA but not in UV, whereas EphB4 
expression is not restricted to UV.  (F)  Virtual Northern blotting with Depp, Cx37, Cx40, 
and IGFBP-5P probes confirms the specific expression of these genes in umbilical 
arteries but not in veins. 
 
Fig. 2. Expression patterns of arterial-specific genes confirmed by in situ hybridization. 
Sections were taken from embryos at E8.75 (A-E), E10.5 (F-J), and E13.5 (K-O). In situ 
hybridization was performed with the anti-sense probes of Flk1 (A, F, K), Depp (B, G, L), 
Cx37 (C, H, M), Cx40 (D, I, N), and IGFBP-5P (E, J, O).  Flk1 is a pan-endothelial 
marker; Depp, Cx37, Cx40 and IGFBP-5P are genes isolated in the differential screen.  
These genes are specifically expressed in the dorsal aorta (arrows) but not in cardinal 
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veins (arrowheads).  IGFBP-5P is also expressed in the notochord from E8.75 to E13.5 
(E, J, O; black arrowheads). Depp is expressed in most enodothelial cells of the dorsa 
aorta at E8.75 (B), but is down-regulated at E10.5 (G) and is completely absent at E13.5 
(L).  However, small, branched vessels from the dorsal aorta still express Depp at E10.5 
(G, black arrowheads and white arrow, respectively) and at E13.5 (L, arrows).  Scale bars, 
100 µm. 
 
Fig. 3. Alignment of DEPP mammalian orthologs and targeting of the Depp locus. (A) 
Amino acid sequences of mouse, human, rat, porcine, and bovine DEPP homologues are 
aligned.  Putative serine- (green circle), threonine- (blue star), and tyrosine-
phosphorylation (red rectangle) sites are marked over the mouse sequence. (B) 
Restriction maps of the wild-type (WT) Depp locus, the targeting vector, and the targeted 
locus.  The targeting vector contains an EGFP-Cre fusion construct fused with the 
initiator codon of Depp, which replaces the whole coding region of Depp (white box). H 
indicates a HindIII restriction enzyme site.  The FRT-flanked PGK-Neo selection cassette 
can be removed by FLPe mediated recombination through mating with FLPe transgenic 
mice. (C) Confirmation of homologous recombination of the targeting vector by Southern 
blotting.  Genomic DNAs of the ES cells were digested with HindIII, and hybridized with 
5’ internal probe A and 3’ external probe B (B).  WT, wild-type locus (14 kb); TG, 
targeted locus (8.7 kb) (D) Genotyping of E11.5 progeny of a Depp heterozygote 
intercross.  Cre primers reveal a 319 bp TG band; Depp wild-type primers, a 269 bp WT 
band. 
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Fig. 4. Arterial-specific and dynamic expression of Depp in the dorsal aorta and forelimb 
at E9.8 and E12.5. E9.8 (A-C, G-I) and E12.5 (D-F, J-L) DeppEGFP-Cre/+; ephrin-B2LacZ/+ 
embryos were sectioned and processed for double-label immunoflouresence staining with 
antibodies to GFP (Gothert et al.) and β-galactosidase (red) to visualize ephrin-B2 
expression.  Samples were analyzed by confocal microscopy.  Depp expression in the 
dorsal aorta (A-F) is quite different from that in the forelimb (G-L).  Note that Depp is 
down-regulated by E12.5 in the dorsal aorta (D-F), but is maintained in E12.5 forelimb 
(J-L).  Note also that all Depp+ endothelial cells are ephrin-B2+.  Arrows indicate dorsal 
aorta and black arrowheads indicate cardinal veins. E9.8 (M-O, S-U) and E12.5 (P-R, V-
X) DeppEGFP-Cre/+; Rosa26R embryos were processed for double-labeling with antibodies 
to GFP (Gothert et al.) and β-galactosidase (red) to visualize cells where Depp-Cre 
mediated recombination occured.  Note that most endothelial cells in the dorsal aorta at 
E9.8 (M-O) and E12.5 (P-R) are β-galactosidase+, indicating Depp-Cre mediated 
recombination.  Scale bars, 100 µm. 
 
Fig. 5. Depp expression in adult organs, P5 retina, tumors and wounded skin. (A-X) 
Depp expression in various organs and tissues from DeppEGFP-Cre/EGFP-Cre mice was 
revealed by double-labeling with antibodies to GFP (Gothert et al.) and PECAM-1 (red).  
The expression pattern from DeppEGFP-Cre/+ mice is similar to, but weaker than the one 
from DeppEGFP-Cre/EGFP-Cre mice; therefore, expression data from DeppEGFP-Cre/EGFP-Cre 
mice were used.  Lewis lung carcinoma cells (S-T) were subcutaneously injected, and 
B16F10 melanoma cells (U-V) were intraperitoneally injected.  Two weeks later, the 
tumors were collected for immunohistochemistry.  (W-X) Skin was removed using a 
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dermal 6 mm biopsy punch, and 7 days later, the wounded skin was excised for 
immunohistochemistry. Scale bars, 100 µm. 
 
Fig. 6. Depp expression in E9.8 heart. (A-I) Triple-labeling with antibodies to GFP (A, D, 
G; green), PECAM-1 (B, E, H; red), and α-SMA (C, F, I; red) on the sections of E9.8 
Depp+/- heart reveals that Depp is expressed in a subset of OFT endocardial cells (G, H; 
arrow) but not in atrial and ventricular endocardial cells (A, B, D, E).  Depp is expressed 
in a subset of myocardial cells of both outflow tracts (G, I; arrowheads) and ventricles (A, 
C, D, F).  (J-R) Triple-labeling with antibodies to β-galactosidase (J, M, P; green), 
PECAM-1 (K, N, Q; red), and α-SMA (L, O, R; red) on the sections of E9.8 DeppEGFP-
Cre/+; Rosa26R heart reveals that Depp-Cre mediated recombination is not observed in 
atrial and ventricular endocardial cells (J, K, M, N) but is observed in OFT endocardial 
cells (P, Q, arrows).  Furthermore, Depp-Cre mediated recombination is observed in both 
OFT (R, arrow) and ventricular (O) myocardial cells.  Unexpectedly, recombination 
occurs in the myocardial cells of trabeculated ventricles (J, L, M, O; arrowheads) and 
atria (J, L; arrows).  Scale bars, 100 µm. 
 
Fig. 7. Depp is not essential for blood vessel development. Whole-mount anti-PECAM-1 
immunoperoxidase staining reveals no obvious differences between Depp+/+ and Depp-/- 
embryos in E9.5 head (A, B), trunk (C, D), and yolk sac (E, F), or in E15.5 forelimb (L, 
J), stomach (K, L), and intestine (M, N).  Double labeling with antibodies to α-SMA 
(Gothert et al.) and PECAM-1 (red) also reveals no evident difference between wild-type 
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and homozygous mutant embryos in E9.5 heart (G, H) and P5 retina (O, P).  Scale bars, 
300 µm. 
 
Fig. 8. Depp is not essential for arterial differentiation, proliferation or apoptosis. (A, B)  
E9.5 Depp+/-;ephrin-B2LacZ/+  and Depp-/-;ephrin-B2LacZ/+ embryos stained with anti- β-
galactosidase antibody to visualize ephrin-B2 expression.  Ephrin-B2 is normally 
expressed in the dorsal aorta of a Depp mutant embryo (B, arrow).  (C-F)  E9.5 Depp+/- 
and Depp-/- embryos were processed for immunolabeling with antibodies to Cx40 (C, D) 
and α-SMA (E, F).  Cx40 and α-SMA are normally expressed in the mutant embryo.  
Arrows indicate dorsal aorta and arrowheads indicate cardinal veins.  (G-J) Double 
labeling with antibodies to GFP (Gothert et al.) and phospho-histone3 (PH3) (red) reveals 
no difference in proliferation between Depp+/- and Depp-/- embryos.  Note that few GFP+ 
endothelial cells in limbs (G, H) are positive for PH3 and none in tails (I, J) are PH3+.  (K, 
L) Double-labeling with TUNEL (Gothert et al.) and anti-PECAM-1 antibody (red) 
reveals no difference in apoptosis between Depp+/- and Depp-/- embryos.  Note that most 
endothelial cells are negative for TUNEL labeling.  Scale bars, 100 µm. 
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Fig. 1. Screening procedure to identify arterial-specific genes 
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Fig. 2. Expression patterns of arterial-specific genes confirmed by in situ hybridization 
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Fig. 3. Alignment of DEPP mammalian orthologs and targeting of the Depp locus 
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Fig. 4. Arterial-specific and dynamic expression of Depp in the dorsal aorta and forelimb 
at E9.8 and E12.5 
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Fig. 5. Depp expression in adult organs, P5 retina, tumors and wounded skin  
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Fig. 6. Depp expression in E9.8 heart 
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Fig. 7. Depp is not essential for blood vessel development  
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Fig. 8. Depp is not essential for arterial differentiation, proliferation or apoptosis 
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Chapter 3 
 
 
A Novel Endothelial Specific Gene, D1.1, is a Marker of Adult Neovasculature 
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ABSTRACT 
Angiogenesis, the sprouting of new blood vessels from pre-existing vessels, is essential 
for tumor growth and wound healing in adults, as well as for proper embryonic 
development. Here we describe a novel endothelial-specific gene, D1.1, which encodes a 
predicted transmembrane protein that is not homologous to any other genes in the 
mammalian genome.  We have examined the expression and function of D1.1 using a 
tau-lacZ knock-in to the endogenous chromosomal locus.   We find that D1.1 is strongly 
expressed by most or all endothelial cells during embryonic development, and is 
subsequently down-regulated in the majority of adult microvessels.  D1.1 is highly up-
regulated and expressed by the majority of endothelial cells during tumor angiogenesis, 
wound healing, and in the corneal micropocket assay.  D1.1 homozygous null mutant 
mice appear phenotypically normal.  However, a soluble D1.1-Fc fusion protein impairs 
endothelial cell migration and blood vessel formation in several different acute assays.  
These data identify D1.1 as a novel marker of neovasculature, and suggest it may play a 
functional role in angiogenesis that is compensated in vivo by other, structurally distinct 
proteins. 
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INTRODUCTION 
Neovascularization, the formation of new blood vessels in adult tissues, is essential for 
tumor growth, wound healing, and a variety of additional physiological and pathological 
process.  For example, inhibition of new blood vessel formation impairs tumor growth, 
and causes necrosis or apoptosis of tumor cells (Hanahan and Folkman, 1996), while 
inhibition of neovascularization in the skin significantly delays wound healing (Streit et 
al., 2000).   
At present, there are only a handful of molecular markers of neovascularization.  Such 
markers are important, for several reasons.  First, they are essential for monitoring the 
process of neovascularization, and its response to different experimental manipulations, 
including drug treatments, in vivo.  Second, they could be used to acutely isolate 
endothelial cells involved in neo-angiogenesis, to compare their properties to those of 
endothelial cells in stable vessels.  Third, such markers could be useful, in humans, for 
early diagnosis of diseases involving new blood vessel formation.  Finally, some markers 
may themselves provide novel targets for pharmacologic inhibition of neovascularization. 
Despite the potential utility of such markers, relatively few genes have been described 
that mark endothelial cells involved in most or all settings of neo-angiogenesis, i.e., pan-
neovessel markers.  Numerous tumor-restricted endothelial genes have been identified 
(Madden et al., 2004; Oh et al., 2004; St Croix et al., 2000); however, it is not clear 
whether any of them serves as a definitive marker of adult neovascularization.  For 
example, some tumor-restricted endothelial markers, such as Flk1, are substantially 
expressed in the endothelial cells of normal adult tissues (Madden et al., 2004).  Others 
are expressed in a subset of endothelial cells of tumor tissues (St Croix et al., 2000), or 
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expressed in certain tumors but not in all tumors (Zheng et al., 2005).  In general, it has 
been difficult to evaluate from the published literature whether any of these markers are 
expressed in all settings of neo-angiogenesis. 
Here we characterize a novel endothelial-specific gene, D1.1, which encodes a 
predicted transmembrane protein.  Using D1.1-LacZ knockin mice, we show that D1.1 is 
highly expressed in most endothelial cells involved in neo-vascularization, using tumor 
angiogenesis, wound healing and corneal micropocket assays.  By contrast, D1.1 is barely 
detectable in the microvasculature of most normal adult tissues, although it is expressed 
in large-diameter vessels.  Homozygous D1.1 mutant mice do not show any obvious 
cardiovascular phenotypic defects.  However, a soluble D1.1-Fc fusion protein has anti-
angiogenic activity in several different assays, suggesting that D1.1 function may be 
compensated in vivo by other, structurally unrelated proteins. 
 
RESULTS 
Isolation of a novel endothelial-specific gene, D1.1 
D1.1 was isolated from a screen originally designed to identify novel arterial- or venous-
specific genes, using single cells from E12 yolk sac as previously described (Dulac and 
Axel, 1995).  cDNAs from these cells were amplified using PCR, and analyzed by 
Southern blotting using four different genes as probes: a house keeping gene, Tubulin; 
two pan-endothelial markers, Flk1 and Flt1; and an arterial marker, ephrin-B2 (data not 
shown).  cDNAs exhibiting comparable expression of these standard genes were selected 
for library construction and screening.  While D1.1 was originally isolated as an arterial-
specific gene, in situ hybridization to E10.5 embryo sections revealed pan-endothelial 
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expression (Supplemental Fig. 1A, C; arrows and arrowheads).  These data also revealed 
that D1.1 expression appeared to be restricted to endothelial and endocardial cells 
(Supplemental Fig. 1B, arrows).   
Reconstruction of a full-length D1.1 cDNA from overlapping ESTs revealed an open-
reading frame that encodes a predicted type I transmembrane protein (Fig. 1B).  The N-
terminal region of D1.1 contains a signal peptide, consisting of the first 18 amino acids, 
and many putative consensus serine- and threonine-glycosylation sites (Fig. 1A, blue and 
red circles), while the C-terminal region contains six putative consensus serine-
phosphorylation sites (Fig. 1A, green circles).  However, D1.1 does not contain any 
conserved structural motifs.   
Sequences of rat, human, bovine, porcine, and chicken D1.1 orthologs have been 
deposited in the public databases, but no apparent orthologs in zebrafish, fugu, or frog 
have been reported.  In addition, there were no other D1.1-related genes in the mouse or 
human genomes.  The transmembrane and cytoplasmic regions are highly conserved 
among the different species examined, whereas the extracellular domain is highly 
divergent (Fig. 1A).  Three out of six putative serine-phosphorylation sites in the 
cytoplasmic region are conserved among the different species, suggesting that D1.1 may 
be involved in an intracellular signaling pathway. 
 
Targeted mutagenesis of D1.1 
To assess the function of D1.1 in vivo, and to characterize its expression in more detail, 
we replaced the first exon (containing the ATG start codon and part of the signal peptide) 
and part of the downstream intron with a tau-LacZ reporter, using homologous 
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recombination in embryonic stem (ES) cells (Fig. 1C).  This construct is designed to 
create a functional null, by preventing membrane insertion of D1.1; a similar targeting 
strategy was previously used to inactivate ephrin-B2 and EphB4 (Gerety et al., 1999; 
Wang et al., 1998).  Germline chimeric mice were then generated from these ES cells by 
blastocyst injection (Fig. 1D). We examined whether homozygous mutant mice transcribe 
D1.1 mRNA by performing RT-PCR using two different 5’ primers and three different 3’ 
primers (Fig. 1F).  Green and red triangles in Fig. 1C and F indicate the relative positions 
of these 5’ primers in the D1.1 locus and D1.1 cDNA; one primer is in the upstream of 
the deleted exon, and the other is downstream of the exon.  The absence of any D1.1 
transcripts in a homozygous mutant embryo and the fact that any splicing to produce a 
truncated form of D1.1 can not make a functional protein due to the absence of the signal 
peptide, clearly indicate D1.1 homozygous mutant is a null mutant (Fig. 1F). 
 
Pan-endothelial expression of D1.1 in embryonic vasculature 
To examine D1.1 expression in detail during embryonic development, we used the tau-
LacZ reporter to perform X-gal staining in E7.5-E9.5 heterozygous embryos.  At E7.5, 
D1.1 was expressed in endocardial cells and the dorsal aorta (Fig. 2A, B; arrows and 
arrowheads); furthermore, it was expressed in small vessels in the head (Fig. 2A, B; open 
arrowheads).  At E8.5 and E9.5, D1.1 was expressed in endocardial but not in myocardial 
cells (Fig. 2C-F, arrows), and in intersomitic vessels as well as in the dorsal aorta (Fig. 
2C, E; open and black arrowheads).  D1.1 was also expressed in endothelial cells around 
the neural tube at E8.5, and in endothelial cells penetrating the neural tube at E9.5 (Fig. 
2D, F; open arrowheads).  D1.1 is expressed in both arterial and venous endothelial cells 
   95
at E9.5 (Fig. 1F, arrowhead vs. open arrow).  By contrast, whole-mount X-gal staining 
revealed, surprisingly, that D1.1 was preferentially expressed in arterial yolk sac 
endothelial cells (Fig. 2G vs. H).  This arterial-enriched expression of D1.1 in the yolk 
sac may explain why D1.1 was originally identified as an arterial-specific gene by the 
differential screen.   
The fact that D1.1 appeared to be expressed in most or all embryonic endothelial cells 
prompted us to directly compare its expression to that of PECAM-1, a pan-endothelial 
marker, using double-immunofluorescent labeling with antibodies to ß-galactosidase and 
PECAM-1.  D1.1 expression was almost identical to PECAM-1 expression in most 
endothelial cells of the brain, the neck region, the liver, the lung, and the heart at E13.5 
(Fig. 3A-I and data not shown).  Double-labeling with antibodies to ß-galactosidase and 
podoplanin, a lymphatic endothelial marker, also revealed that D1.1 was expressed in 
lymphatic endothelial cells (Fig. 3J-L, arrows).  Taken together, these data suggest that 
D1.1 is a pan-endothelial (blood endothelial and lymphatic endothelial) marker in the 
embryonic vasculature. 
 
D1.1 expression is down-regulated in most adult microvessels 
We next examined whether the endothelial expression of D1.1 is maintained in adult 
vasculature, by performing double-labeling with antibodies to ß-galactosidase and 
PECAM-1.  Strikingly, D1.1 was strongly down-regulated in the microvessels of most 
organs and tissues examined.  For example, such down-regulation was clearly detected in 
brain, liver, kidney, stomach, pancreas and heart (Fig. 4A-R, arrowheads).  This down-
regulation was particularly evident in brain, where D1.1 was virtually absent (Fig. 4A-C).  
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However, a subset of vessels detectably expressed D1.1 in some other tissues (Fig. 4D-R).  
For example, D1.1 was relatively highly expressed in a subset of large-diameter vessels 
in kidney, stomach, pancreas, and heart (Fig. 4G-R, arrows).  In the pancreas, the level of 
D1.1 expression in some microvessels is similar to that in the large-diameter vessels (Fig. 
4M-O, open arrows vs arrows).  Expression of D1.1 in the heart was particularly complex, 
with microvessels in different regions (atrium, interventricular septum) expressing the 
gene to different extents (Supplemental Fig. 2).  Despite these exceptions, these data 
suggest that, in general, D1.1 is down-regulated in most microvessels, but maintained in a 
subset of large-diameter vessels. 
 
D1.1 expression is maintained in postnatal tissues undergoing active neo-
angiogenesis 
Interestingly, D1.1 was relatively highly expressed in most vessels of the ovary and the 
uterus (Fig. 5A-F).  The fact that physiological angiogenesis occurs in the ovary where 
D1.1 was highly expressed prompted us to examine other physiologically angiogenic 
tissues such as the placenta and the retina.  D1.1 was highly, homogeneously expressed in 
all the vessels of the placenta taken from a pregnant heterozygous female bearing E9.5 
embryos, whereas it was barely expressed in the vessels of the placenta from a female 
bearing E16.5 embryos (Fig. 5G-L).  Furthermore, D1.1 was strongly expressed in the 
vessels of P5 retina, whereas it was down-regulated in the vessels of adult retina (Fig. 
5M-R).  Whole-mount X-gal staining of P5 and adult retina clearly revealed the down-
regulation of D1.1 in adult retinal vessels (Fig. 5S, T).  Taken together, these data 
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suggested that D1.1 may be expressed when angiogenesis occurs, then down-regulated 
when angiogenesis ceases.  
 
Strong up-regulation of D1.1 in most vessels during tumor angiogenesis, wound 
healing, and in the corneal micropocket assay 
To investigate further the idea that D1.1 broadly marks endothelial cells involved in 
neovascularization, we examined D1.1 expression in a variety of settings of adult 
neovascularization: tumors, wound healing and the corneal micropocket assay.  D1.1 was 
highly expressed in most endothelial cells of Lewis lung carcinoma (LLC) tumors and 
B16F10 melanoma tumors grown subcutaneously (Fig. 6A-C and data not shown).  D1.1 
was also abundantly expressed in most vessels during wound healing, while in normal 
skin it was expressed in only a subset of vessels (Fig. 6G-I, arrows).  In addition, D1.1 
was highly expressed in the corneal neovasculature induced by bFGF (Fig. 6P-R).  
Although D1.1 was still expressed in most limbic endothelial cells of the untreated eye 
(Fig. 6M-O, arrows), its expression in the neovessels was a little higher than that in the 
limbic vessels of the untreated eye.  Whole-mount X-gal staining also revealed that D1.1 
was strongly expressed in the corneal neovessels growing toward bFGF-containing 
pellets (Fig. 6T, U), but moderately expressed in the stable vessels (Fig. 6S).   
Although D1.1 was more strongly expressed in neovessels than in the stable vessels of 
surrounding tissues, it is not clear whether D1.1 expression in neovessels is caused by the 
induction of D1.1 in neovessels or by the recruitment of D1.1+ endothelial cell from 
surrounding tissues.  To clarify this issue, B16F10 melanoma cells were implanted into 
the brain, where D1.1 was barely expressed, and the tumors taken from the brain were 
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processed to examine D1.1 expression by double-labeling with antibodies to ß-
galactosidase and PECAM-1.  D1.1 was expressed in the endothelial cells of the tumor 
vessels, but not of surrounding brain vessels (Fig. 6J-L, arrows vs. arrowheads), 
suggesting that D1.1 expression in the endothelial cells of tumor vessels is caused by the 
induction of D1.1, not by the recruitment of D1.1+ endothelial cells from surrounding 
tissues.  Taken together, these data suggest that D1.1 provides a marker of neovasculature.  
 
D1.1 is not essential for vessel development or maintenance 
The pan-endothelial expression of D1.1 during development prompted us to examine the 
cardiovascular phenotype of D1.1 homozygous mutant embryos.  Whole-mount staining 
with anti-PECAM-1 antibodies revealed no obvious differences in vessel development or 
patterning of E9.5 embryos (Fig. 7A, B), E9.5 yolk sacs (Fig. 7C, D), or E12.5 trunk 
neural tubes between wild-type and homozygous mutant mice.  Whole-mount X-gal 
staining also revealed no obvious differences in vessel development or patterning of the 
retina, uterus, intestine, bladder, stomach, or the testis between P5 or P9 heterozygous 
and homozygous mutant mice (Fig. 7G-L and data not shown).  The increased X-gal 
intensity in homozygous mutant mice likely reflects the additional copy of the D1.1-
tauLacZ gene.  D1.1 homozygous mutant mice develop normally without any apparent 
physiological or developmental defects, and are fertile in both a 129/c57Bl6 mixed 
background and a pure 129 background. 
D1.1 was highly expressed in endothelial cells during tumor angiogenesis and wound 
healing.  We therefore asked whether pathological angiogenesis in tumors and during 
wound healing was affected in homozygous mutant mice, by implanting Lewis lung 
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carcinoma or B16F10 melanoma cells subcutaneously or by making skin wounds in the 
back of the mutant mice.  The tumor size and extent of vascularization, and the rate and 
extent of wound healing and skin vascularization in homozygous mutant mice, were 
similar to those in heterozygous and wild-type mice (data not shown).  We also 
performed corneal micropocket assays by inserting bFGF-containing pellets into the 
corneas of the mutant mice (data not shown), but no obvious differences were apparent. 
 
D1.1-Fc proteins impair angiogenesis in several angiogenesis assay 
The lack of an obvious phenotype in D1.1 homozygous mutant mice suggested that its 
function might be compensated during development by other genes.  To circumvent this 
problem, we sought a means of acutely interfering with the function of D1.1 and/or 
interacting proteins.  The functions of many single-pass transmembrane proteins have 
been analyzed using soluble proteins, consisting of their extracellular domain fused to the 
Fc region of human immunoglobulin (Davis et al., 1994; Suchting et al., 2005).  We 
therefore generated a D1.1-Fc fusion protein using the baculovirus expression system 
(see Methods).  These D1.1-Fc proteins were used to analyze the functions of D1.1 in 
various in vitro and in vivo angiogenesis assays.   
The chick chorioallantoic membrane (CAM) assay measures natural vessel growth 
(Oreilly et al., 1994).  This assay revealed that vessels did not grow around filter discs 
containing a D1.1-Fc protein, but did grow normally around filter discs containing a 
control Fc protein (Fig. 8A, B).  Quantification of vessel density around the discs 
confirmed the robust inhibition of vessel growth by D1.1-Fc (Fig. 8C).  Preliminary 
experiments using another CAM assay, which measures bFGF-induced vessel growth 
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(Brooks et al., 1994), indicated that D1.1-Fc significantly reduced bFGF-induced vessel 
branching in this assay as well (data not shown).   
The allantois assay was performed to check whether the murine D1.1-Fc protein can 
impair angiogenesis occurring in mouse tissues, as well as in chick.  This assay tests for 
anti-angiogenic activity using cultured E8.5 mouse embryonic allantoises incubated with 
test reagents for 18-22 hours (Argraves et al., 2002; Drake and Fleming, 2000).  Rather 
than blocking vessel growth completely (Crosby et al., 2005), preclustered D1.1-Fc 
perturbed vascular patterning, resulting in a significant enlargement of average vessel 
diameter (Fig. 8D-F).  This effect occurred mainly for vessels at or near the surface of the 
cultured allantoises, likely reflecting a lack of efficient penetration of the D1.1-Fc fusion 
deeper into the explant. 
In addition, D1.1-Fc significantly inhibited spontaneous and VEGF-induced trans-well 
migration of human umbilical vein endothelial cells (HUVEC) (Fig. 8G).  However, the 
effect of D1.1-Fc to impair cell migration in vitro can be overridden by factors that 
strongly promote the activity, such as bFGF (Fig. 8G).  Taken together, these data 
suggest that a D1.1-Fc fusion protein may have anti-angiogenic activity in certain in vitro 
and in vivo assays.  
 
DISCUSSION 
In this study, we identified a novel endothelial-specific gene, D1.1, as a molecular marker 
of adult neovasculature as well as embryonic vasculature based on several features of 
D1.1 expression, by generating D1.1-LacZ knockin mice and by taking advantage of the 
LacZ reporter for the detailed expression analysis of D1.1.  First, D1.1 is homogeneously 
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expressed in most endothelial cells of embryonic vasculature, whereas it is barely or 
weakly expressed in microvessels of most adult tissues.  Second, D1.1 is highly 
expressed in the vessels of physiologically angiogenic tissues such as the ovary, the 
placenta, and the retina, whereas it is down-regulated in the placenta and the retina when 
angiogenesis ceases.  Third, D1.1 is highly up-regulated in most vessels during tumor 
angiogenesis and wound healing and in the corneal micropocket assay.  In addition to the 
characteristic of D1.1 as a neovessel marker, D1.1 expression in normal adult tissues 
reveals heterogeneity of endothelial cells among different tissues and even in the same 
tissue.  Furthermore, a soluble D1.1-Fc protein impaired angiogenesis in the chick CAM 
and mouse allantois assays, and inhibited the migration of HUVEC cells, suggesting that 
D1.1 may play a role in angiogenesis. 
 
D1.1 is a marker of adult neovasculature 
The fact that D1.1 is strongly, homogeneously expressed in most endothelial cells of 
various neo-angiogenic tissues, whereas it is barely or weakly expressed in microvessels 
of most normal tissues suggests D1.1 as a marker of adult neovasculature.  Many tumor-
restricted endothelial genes have been reported (Madden et al., 2004; Oh et al., 2004; St 
Croix et al., 2000), but few of them have been used as a definitive marker of 
neovascularization.  
In addition to these tumor-restricted genes, several genes expressed in endothelial cells 
during development were recently reported to be induced in tumor vasculature and down-
regulated in normal adult tissues, suggesting that they may be a possible marker of adult 
neovasculature.  EGF-like domain 7 (Egfl7), a secreted factor from endothelial cells, is 
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expressed at high levels in the vasculature associated with tissue proliferation, and is 
down-regulated in most mature vessels of normal adult tissues; however, it is expressed 
in a subset of the neovasculature, but not in most endothelial cells of the neovessels 
(Parker et al., 2004).  In addition, Egfl7 is expressed in a subset of vessels in some 
normal organs such as the lung, the kidney, and the heart (Parker et al., 2004; Soncin et 
al., 2003).  Delta-like 4 (Dll4), a membrane-associated Notch ligand, is induced in a 
subset of vessels in tumors, but not in most tumor vessels; is also expressed in smaller 
arteries and microvessels in normal adult tissues (Gale et al., 2004).  Ras guanine-
releasing protein 3 (RasGRP3), a guanine exchange factor, is up-regulated in maternal 
vessels of the decidua and in tumor vessels, and is expressed in the endothelial cells of 
the kidney glomerulus, but not of most adult tissues; however, it is not clear from the 
limited published data whether RasGRP3 is expressed in most, or just a subset, of the 
neovessels (Roberts et al., 2004).   
In contrast to these genes, D1.1 is strongly, homogeneously expressed in most vessels 
in tumors, during wound healing, and in bFGF-treated corneas, and barely or weakly 
expressed in the microvessels of most adult tissues although it is expressed in some of 
large-diameter vessels.  Therefore, D1.1-LacZ mice will be a useful resource to monitor 
neovascularization in mouse models of angiogenesis-dependent diseases such as tumors. 
  
The distinct expression of D1.1 between large-diameter vessels and microvessels 
Microvessels are the main sites for angiogenesis in adults, and many genes associated 
with angiogenesis are specifically expressed in microvascular endothelial cells but not in 
the endothelial cells of large vessels in adults (Chi et al., 2003), suggesting that adult 
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microvessels are more similar to  embryonic vessels than to adult large vessels because 
angiogenesis occurs during development.  For example, Flk1 is expressed in most 
embryonic endothelial cells, is maintained in microvessels but not in large vessels of 
adult tissues, and induced in adult neovasculature (data not shown).   
In contrast to Flk1, D1.1 is relatively highly expressed in large vessels but not in 
microvessesls of adult tissues (Fig. 4G-R, arrows vs. arrowheads), although it is similarly 
expressed in most endothelial cells of embryonic vessels and adult neovasculature.  
Therefore, D1.1 expression is not consistent with the general concept that microvessels 
are more similar to embryonic vessels than to large vessels in adults.  The robust 
expression of D1.1 in adult neovessels suggests D1.1 expression may be regulated by 
angiogenesis-related signals, which may not exist around stable large-diameter vessels; 
thus, D1.1 expression in stable large-diameter vessels might be regulated independently 
of angiogenesis-related signals.  It would be of interest to examine which enhancer 
elements in the D1.1 locus and which factors control this distinct expression of D1.1 
between large vessels and microvessels in adults. 
 
Possible Functions of D1.1 in angiogenesis based on D1.1-Fc activities 
Despite its endothelial-specific expression and the absence of any other D1.1-related 
genes in the mouse genome, D1.1 homozygous mutant mice did not show any detectable 
phenotypic defects during development or in adulthood, preventing us from deducing any 
possible functions of D1.1 from homozygous mutant mice.   
Although D1.1 ECD sequences are divergent among different species and chicken 
D1.1 ECD sequence was not reported due to the incomplete chicken genome sequencing 
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(Fig. 1A), mouse D1.1-Fc protein impaired angiogenesis in the chick CAM assay and in 
vitro assay using HUVEC cells as well as in mouse allantois assay, suggesting that D1.1 
ECD might be structurally conserved among different species and D1.1 may play roles in 
angiogenesis.   
D1.1-Fc inhibited spontaneous vessel growth and bFGF-induced angiogenesis in the 
chick CAM assays, impaired proper vascular remodeling in mouse allantois assay, and 
inhibited the migration of HUVEC cells, indicating that D1.1-Fc appears to be an 
inhibitor of angiogenesis.  However, it is not clear from the present studies whether D1.1-
Fc acts as an agonist or antagonist.  If D1.1-Fc acted as an agonist, D1.1 might have anti-
angiogenic activities, of which blocking might increase angiogenesis, and the up-
regulation of D1.1 in neovasculature might be a part of the negative feedback mechanism 
to control excessive vessel growth.  If D1.1-Fc acted as an antagonist, D1.1 might have 
pro-angiogenic activities, of which blocking might inhibit angiogenesis, and the up-
regulation of D1.1 in neovasculature might be part of the positive feedback mechanism to 
promote angiogenesis. 
 
EXPERIMENTAL PROCEDURES 
Preparation and screening of Single-Cell cDNA libraries 
The middle regions of E12 yolk sacs were dissected in HBSS, and dissociated into single 
cells by digestion with type 1 collagenase (Worthington).  Under a microscope, single 
cells were transferred using a mouth pipette into tubes containing lysis buffer, and 
processed for single-cell based PCR amplification, essentially as described (Dulac and 
Axel, 1995).  Each 5 µg of the amplified cDNAs were loaded on 1.5% agarose gels for 
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electrophoresis to check the quality of the cDNAs, and transferred into a Hybond-N+ 
membrane (Amersham) followed by Southern blotting using 3’-biased cDNA probes 
against a house keeping gene, Tubulin; two pan-endothelial markers, Flk1 and Flt1; and 
an arterial endothelial marker, ephrin-B2.  The single-cell cDNAs positive for Tubulin, 
Flk1, Flt1, and ephrin-B2 were considered arterial endothelial cDNAs, while ones, which 
are positive for Tubulin, Flk1, and Flt1 and negative for ephrin-B2, were considered as 
venous endothelial cDNAs.  One pair of cDNAs was selected for further steps of the 
differential screen. 
 
Generation of D1.1 null mutant allele 
The arms of the D1.1 targeting construct (left arm, 2.7 kb; right arm, 5.2kb) were 
subcloned from a 129/SvJ genomic DNA BAC clone (Incyte).  A tau-LacZ reporter and a 
self-excised ACN selection cassette was inserted into the start codon of D1.1, by 
replacing the first exon and the part of the first intron of D1.1 (total 51 bp).  Homologous 
recombination was performed in mouse CJ7 embryonic stem (ES) cells following 
standard procedures. Correctly targeted ES cell clones were identified by Southern blot 
hybridization using 5’ and 3’ external probes. Chimeric mice were produced by 
blastocyst injection and were mated to C57Bl/6 mice to establish lines.  The D1.1 allele 
was deposited as MGI:3526088.  The ACN selection cassette was self-excised in the 
chimeric sperm, whose progenies do not contain the ACN cassette in their genome 
(Bunting et al., 1999).  To clarify whether this mutant is null or hypomorphic, two 5’ 
primers (a, 5'-AGTACT CCCTCTCTCTTCTCTACT-3'; b, 5'-
GAGAAGCATCTCTGGATGCTACTC-3') and three 3’ primers (c, 5'-
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GTTCACGTTGATGTTCCTCATGGA-3'; d, 5'-
TTAAAGAATCTTCTCTGCTGACATGCTG-3'; e, 5'-
CTAGTAGAATGGACAATCTACCTC-3' ) were used in all possible combinations for 
RT-PCR using E10.5 embryonic cDNAs from a heterozygote and a homozygote as a 
template (Fig. 1F). 
 
Genotyping 
The genotyping of D1.1 mutant mice was performed by PCR using two primer sets 
detecting the wild-type and the mutant allele: WT1 (5’- 
CATCTCACCCCAGTACTCCCTC-3’) and WT2 (5’-
CCTTGGAGCAGGAGTAAACCGAGA-3’) primers, 142 bp PCR products; LacZ1 (5'-
CGCCCGTTGCACCACAGATG-3') and LacZ2 (5'-
CCAGCTGGCGTAATAGCGAAG-3') primers, 370 bp PCR products.   
 
Immunohistochemistry 
Embryos and adult organs were fixed for 6-8 hours in 4% paraformaldehyde/PBS at 4°C, 
washed with PBS, sunk in 30% sucrose/PBS overnight at 4°C, frozen in OCT medium, 
and 20 µm sections were collected on a cryostat.  Staining was performed using anti-
PECAM-1 antibody (Pharmingen, 1:300 overnight at 4°C), anti-ß-galactosidase antibody 
(5-prime 3-prime, 1:1000, overnight at 4°C), Cy3-conjugated anti-α-SMA antibody 
(Sigma, 1:500, 40 minutes at room temperature), and anti-podoplanin antibody 
(Developmental Studies Hybridoma Bank, 8.1.1, 1:100, overnight at 4°C),   For 
immunofluorescent detection; FITC-, Cy3-, Cy5-, Alexa-488-, or Alexa-568-conjugated 
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secondary antibodies (Jackson, 1:300; Molecular Probes, 1:250, 40 minutes at room 
temperature) were used.  All confocal microscopy was carried out on a Leica SP confocal 
(Leica).   
For whole-mount staining, embryos and organs were first fixed for 1-2 hours in 4% 
paraformaldehyde/PBS at 4°C, washed with PBS, and dehydrated in 100% methanol at -
20°C.  Staining was performed with anti-PECAM1 antibody (Pharmingen, 1:200 
overnight at 4°C) and anti-ß-galactosidase antibody (5-prime 3-prime, 1:1000, overnight 
at 4°C); either HRP-conjugated secondary antibodies (Jackson, 1:300, overnight at 4°C) 
or secondary antibodies conjugated to Cy5- or Alexa-488 (Jackson, 1:300, and Molecular 
Probes 1:250, 1 hour at room temperature) were used. 
 
LacZ staining
Embryos and organs were dissected, fixed in 0.25% glutaraldehyde/PBS for 5-15 
minutes, rinsed twice with PBS, and stained at 37°C in X-Gal buffer [1.3 mg/ml 
potassium ferrocyanide, 1 mg/ml potassium ferricyanide, 0.2% Triton X-100, 1 mM 
MgCl2 and 1 mg/ml X-Gal in phosphate-buffered saline (PBS, pH 7.2)].  The stained 
embryos were post-fixed in 4% paraformaldehyde/PBS at 4°C, washed with PBS, were 
embedded in 15% sucrose and 7.5% gelatin in PBS, and 20 µm sections were collected on 
a cryostat.  All bright-field images were captured using an Axiocam CCD camera (Zeiss). 
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In situ hybridization 
In situ hybridization was carried out essentially as described (Wang et al., 1998).  
Embryos were cryosectioned at 20 µm, and hybridized with a cRNA probe against D1.1 
(750 bp). 
 
Pathological studies: tumors, cutaneous wounding, and corneal micropocket assay 
All procedures were carried out under protocols reviewed and approved by the IACUC 
(Institute Animal Care and Use Committee).  Mice were implanted subcutaneously with 
200 µl of 2 x 106 Lewis lung carcinoma cells (LLC) or B16F10 melanoma cells, and 
sacrificed between 13 to 15 days post-implantation when the diameter of the tumors 
reached 1.5 cm.  The tumors were dissected, weighed, fixed for 6-8 hours in 4% 
paraformaldehyde/PBS at 4°C, cryoprotected overnight in 30% sucrose/PBS at 4°C, 
frozen in OCT medium, and 20 µm sections were collected on a cryostat.  
For brain tumors, 2 µl of 1 x 105 B16F10 melanoma cells were implanted into the 
brain, as described (Papadopoulos et al., 2004).  The mice were sacrificed in 6 days post-
implantation, and the brain was removed and processed for immunofluorescence staining 
like subcutaneous tumors. 
Full-thickness cutaneous wounds were made on the back skin of mice using a sterile, 
disposable 6-mm dermal biopsy punch (Miltex).  Seven days later, animals were 
sacrificed and the tissue was examined. 
The mouse corneal micropocket assay was performed as described previously 
(Kenyon et al., 1996) using hydron-coated sucralfate pellets containing 100 ng of bFGF 
(PeproTech).  For LacZ staining, the entire eye was first stained, and the cornea was 
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dissected out and flat-mounted on a slide whose coverslip was elevated by a bridge of two 
coverslips on each side to avoid crushing the cornea.  For immunofluorescent staining, 
the entire eyes were fixed and sectioned on a cryostat.  
 
Production of Fc and D1.1-Fc fusion proteins 
D1.1 extracellular region including signal peptide sequences and human IgG1 Fc region 
were amplified by PCR, and inserted together into the baculovirus expression vector 
pBacPAK8 (CLONTECH) to make D1.1-Fc fusion construct.  For Fc construct, human 
IgG1 Fc region was amplified by PCR with a primer containing D1.1 signal peptide 
sequences, and cloned into pBacPAK8 vector; thus, both D1.1-Fc and Fc constructs 
contain the same signal peptide sequences, which make the proteins secreted into the 
culture media.  The baculovirus/insect cell expression system was used, and the secreted 
proteins were purified over protein-A columns (Pierce).  
 
Cell culture 
Human umbilical vein endothelial cells (HUVEC-2) were purchased from BD Bioscience 
and cultured in Medium 200 (Cascade Biologics) containing Low Serum Growth 
Supplement (Cascade Biologics), as recommended in the product sheet. Cells were not 
used beyond the sixth passage. 
 
Endothelial cell migration assay 
Analysis of HUVEC migration was performed using the angiogenesis endothelial cell 
migration kit (BD Bioscience); 5 × 104 HUVEC per well were seeded into the upper 
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chamber of the migration plate insert in migration media (Medium 200 + 0.4% FCS). The 
bottom chambers were loaded with or without VEGF (10 ng/ml) or bFGF (10 ng/ml) in 
750 µl total volume of migration media in the presence of D1.1-Fc or Fc. After 22 h of 
incubation at 37°C, the insert membranes were stained with 4 µg/ml Calcein AM 
(Molecular Probes) in Hanks’ balanced salt solution for 90 min. Fluorescence on the 
under side of the membrane was measured at excitation/emission wavelengths of 485/530 
nm using a fluorescence microplate reader. 
 
Chick CAM assay 
The CAM assay to measure spontaneous vessel growth was performed, as described 
(Oreilly et al., 1994).  Briefly, 3-d-old fertilized white Leghorn eggs (Spafas, Inc., 
Norwich, CT) were cracked, and chick embryos with intact yolks were placed in 100 X 
20 mm plastic Petri-dishes. After 3 d of incubation in 3% CO2 at 37°C, a disk of 
methylcellulose containing D1.1-Fc or Fc was implanted on the CAM of individual 
embryos. After 48 h of incubation, embryos and CAMs were analyzed for the formation 
of avascular zones by a stereomicroscope. 
The CAM assay, which measures bFGF-induced angiogenesis, was performed as 
described (Brooks et al., 1994).  Filter discs saturated with D1.1-Fc or Fc proteins along 
with 100 ng/ml bFGF were placed on the CAMs of 10-d-old chick embryos. After 72 h, 
filter discs and associated CAM tissues were harvested and quantified. Angiogenesis was 
assessed as the number of visible blood vessel branching points within the defined area of 
the filter discs. 
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Allantois explant culture 
Allantoises were dissected from E8.5 mouse embryos and cultured for 18 hours (37°C, 
5% CO2) in the presence of pre-clustered D1.1-Fc or Fc proteins, as described (Argraves 
et al., 2002; Drake and Fleming, 2000).  D1.1-Fc or Fc proteins were pre-clustered, by 
incubating with anti-human Fc antibodies (Jackson) for 30 minutes at room temperature.  
Allantoises were fixed and processed for immunofluorescence staining with anti-
PECAM-1 antibody (Pharmingen, 1:300 overnight at 4°C).   
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FIGURE LEGENDS 
Fig. 1. Alignment of D1.1 orthologs and targeting of the D1.1 locus. (A) Amino acid 
sequences of mouse, rat, human, bovine, porcine, and chicken D1.1 orthologs are aligned.  
Signal peptide and transmembrane sequences (black bars) are marked over the mouse 
sequence; putative serine-phosphorylation (green circles), and threonine- (red circles) and 
serine-glycosylation (blue circles) sites are marked over the sequence. (B) Imaginary 
diagram of D1.1 topology to show the relative position of its N- and C-terminal. (C) 
Schematic representation of the wild-type (WT) D1.1 locus, the targeting vector, and the 
targeted locus in ES cells and F1 progenies.  The targeting vector contains a tau-LacZ 
reporter and a self-excised selection ACN cassette, by replacing the first exon and the 
part of the first intron of D1.1 (total 51 bp). (D) Confirmation of homologous 
recombination of the targeting vector by Southern blotting. Genomic DNAs of the ES 
cells were digested with NcoI and RcaI, and hybridized with 5’external probe A and 3’ 
external probe B, respectively.  WT, wild-type locus (14 kb for probe A, 12 kb for probe 
B); TG, targeted locus (9.5 kb for probe A, 9 kb for probe B) (E) Genotyping of E10.5 
progeny of a D1.1 heterozygote intercross. LacZ primers reveal 370 bp TG band; D1.1 
wild-type primers, a 142 bp WT band. (F) Confirmation of D1.1 null mutation by RT-
PCR. Two different 5’ primers (a, green triangle; b, red triangle) and three different 3’ 
primers (c-e) were used to amplify cDNAs from heterozygous and homozygous mutants.  
Their relative position in D1.1 cDNA was marked with start (ATG) and stop (TAA) 
codons; white box represents the deleted region in the targeting construct. 
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Fig. 2. D1.1 expression during early development. E7.5 (A, B), E8.5 (C, D), and E9.5 (E, 
F) D1.1LacZ/+ embryos were processed for whole mount X-gal staining, and sectioned (B, 
D, F); E9.5 arterial (G) and venous (H) part of D1.1LacZ/+ yolk sac was processed for 
whole mount X-gal staining.  Arrows indicate endocardial cells and arrowheads indicate 
dorsal aortic endothelial cells.  Open arrowhead in A, endothelial cells in the head; ones 
in B, microvessels; ones in C and E, intersomitic vessels; one in D, endothelial cells 
around the neural tube; one in F, endothelial cells inside the neural tube; open arrow in F, 
venous endothelial cells.  Dotted lines in A, C, and E represent the position of sections 
shown in B, D, and F, respectively. Scale bars, 300 µm. 
 
Fig. 3. Pan-endothelial expression of D1.1 in E13.5 embryos. E13.5 D1.1LacZ/+ embryos 
were sectioned and processed for double-label immunoflouresence staining with 
antibodies to β-galactosidase (Gothert et al.) and PECAM-1 (red) (A-I), or with 
antibodies to β-galactosidase (Gothert et al.) and podoplanin, a lymphatic endothelial 
marker (red) (J-L).  D1.1 expression is very similar to PECAM-1 expression in the brain 
(A-C), the neck region (D-F), and the liver (G-I); D1.1 is expressed in lymphatic 
endothelial cells (J-L, arrows) as well as arterial and venous endothelial cells (J-L, open 
and closed arrowheads). Scale bars, 100 µm. 
 
Fig. 4. D1.1 is barely or weakly expressed in the microvessels of most adult tissues.  
Adult D1.1LacZ/+ mice were sectioned and processed for double-label immunoflouresence 
staining with antibodies to β-galactosidase (Gothert et al.) and PECAM-1 (red).  (A-C) 
D1.1 is barely expressed in vessels of the brain.  (D-E) D1.1 is weakly expressed in a 
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small subset of the microvessels of the liver.  (G-H) In the kidney, D1.1 is mainly 
expressed in large-diameter vessels (arrows), but not in the microvessels (arrowheads).  
(J-L) D1.1 is strongly expressed in the large vessels of the stomach (arrows), but barely 
expressed in the microvessels (arrowheads).  (M-O) In the pancreas, D1.1 is strongly 
expressed in the large vessels (arrows), but weakly expressed in a subset of the 
microvessels (arrowheads). (P-R) D1.1 is expressed in a subset of the large vessels and 
the microvessels (arrows and arrowheads) of the heart. Scale bars, 100 µm. 
 
Fig. 5. D1.1 is highly expressed in adult tissues where physiological angiogenesis occurs. 
(A-L) Adult D1.1LacZ/+ mice were sectioned and processed for double-label 
immunoflouresence staining with antibodies to β-galactosidase (Gothert et al.) and 
PECAM-1 (red).  D1.1 is highly expressed in the ovary (A-C), the uterus (D-F), and the 
placenta of E9.5 bearing females (G-I), but barely expressed in the placenta of E16.5 
bearing females (J-L). (M-R) P5 and adult D1.1LacZ/LacZ retinas were processed for whole-
mount double-labeling with antibodies to β-galactosidase (Gothert et al.) and PECAM-1 
(red).  D1.1 is strongly expressed in the arterial and venous vessels of P5 retinas as well 
as the microvessels (M-O, arrows and arrowheads), but faintly expressed in a subset of 
the vessels of adult retinas (P-R).  (S-T) P5 and adult D1.1LacZ/+ retinas were processed 
for whole-mount X-gal staining, revealing the strong expression of D1.1 in P5 retinas (S) 
and the down-regulation of D1.1 in adult retinas (T). Scale bars, 100 µm. 
 
Fig. 6. D1.1 is highly up-regulated in the neovasculature in tumors, during wound healing, 
and in the corneal micropocket assay. Adult D1.1LacZ/+ mice were used for D1.1 
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expression analysis.  Immunofluorescence staining with antibodies to β-galactosidase 
(Gothert et al.) and PECAM-1 (red) was performed on the sectioned tissues of Lewis 
lung carcinomas grown subcutaneously (A-C), wounded skin (D-F), normal skin (G-I), 
B16F10 melanomas grown in the brain (J-L), normal sclerocorneal junction (M-O), and 
bFGF-treated corneas (P-R).  D1.1 is highly expressed in most neovessels, whereas it is 
expressed in a subset of the vessels of normal skin, so there are a number of D1.1- vessels 
in the skin (G-I, arrows and arrowheads).  D1.1 is induced in the vessels of B16F10 
melanomas grown in the brain, in which D1.1 is barely expressed (J-L, arrows vs 
arrowheads).  The tumor boundary is marked by dashed lines.  D1.1 is expressed in the 
limbic vessels at the sclerocorneal junction and in the vessels of the iris (M-O, arrows and 
arrowheads). (S-U) An untreated cornea and bFGF-treated corneas for 3 days and 6 days 
were processed for whole-mount X-gal staining, and were flat-mounted for photograph.  
Arrows indicate bFGF-containing pellets. Scale bars, 100 µm. 
  
Fig. 7. D1.1 is not essential for normal vessel development. Whole-mount anti-PECAM-
1 immunoperoxidase staining reveals no obvious differences between wild type and D1.1 
homozygous mutant mice in the vasculature of E9.5 embryo (A, B), yolk sac (C, D), and 
E12.5 neural tube (E, F).  Whole-mount X-gal staining also reveals no obvious 
differences between P5 D1.1+/- and D1.1-/- littermates in the vasculature of the retina (G, 
H), the uterus (I, J), and the intestine (K, L). Scale bars, 300 µm. 
 
Fig. 8. Soluble D1.1-Fc protein impairs angiogenesis. (A-C) The chick chorioallantoic 
membrane (CAM) assay measuring spontaneous vessel growth reveals that D1.1-Fc (4 
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µg) inhibits spontaneous vessel growth.  The arrows denote the position of the 
methylcellulose pellets containing D1-1 Fc or Fc proteins.  The vascular density around a 
disk from each 10 CAMs was measured; results are means and s.e.m. (D-F) Mouse 
allantois explant culture reveals that pre-clustered D1.1-Fc (250 µg/ml) impairs the 
proper vascular pattering. The diameter of vessels was randomly measured from the 
surface regions of three different allantoises, and results are means and s.e.m. Scale bars, 
100 µm. (G) D1.1-Fc (100 µg/µl) inhibits spontaneous and VEGF-induced migration of 
HUVEC cells, but does not significantly inhibit bFGF-induced migration.  Results are 
means and standard deviations from each triplicate.   
 
Supplemental Fig. 1. In situ hybridization of D1.1 at E10.5. The staining of the trunk (A, 
B) and the tail (C) regions reveals that D1.1 is expressed in arterial (A,C; arrows) and 
venous (A,C; arrowheads) endothelial cells, and endocardial cells (arrows in B). Scale 
bars, 100 µm. 
 
Supplemental Fig. 2. Heterogeneous expression of D1.1 in adult heart. Adult D1.1LacZ/+ 
heart was sectioned and processed for double-label immunoflouresence staining with 
antibodies to β-galactosidase (Gothert et al.) and PECAM-1 (red).  D1.1 is highly 
heterogeneously expressed in the different regions of the heart: the right ventricle (A-C), 
the interventricular septum (D-L), the left ventricle (M-O), and the left atrium (P-R). 
Scale bars, 100 µm. 
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Fig. 1. Alignment of D1.1 orthologs and targeting of the D1.1 locus 
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Fig. 2. D1.1 expression during early development 
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Fig. 3. Pan-endothelial expression of D1.1 in E13.5 embryos 
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Fig. 4. D1.1 is barely or weakly expressed in the microvessels of most adult tissues 
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Fig. 5. D1.1 is highly expressed in adult tissues where physiological angiogenesis occurs 
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Fig. 6. D1.1 is highly up-regulated in the neovasculature in tumors, during wound healing, 
and in the corneal micropocket assay 
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Fig. 7. D1.1 is not essential for normal vessel development 
   128
 
 
Fig. 8. Soluble D1.1-Fc protein impairs angiogenesis 
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Supplemental Fig. 1. In situ hybridization of D1.1 at E10.5
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Supplemental Fig. 2. Heterogeneous expression of D1.1 in adult heart 
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Chapter 4 
 
 
Future Directions 
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Investigation of ephrin-B2 function in arterial smooth muscle cells 
Ephrin-B2 is expressed in arterial smooth muscle cells (SMCs) as well as in arterial 
endothelial cells (Gale et al., 2001; Shin et al., 2001).  The essential role of ephrin-B2 in 
arterial endothelial cells was revealed by the analysis of ephrin-B2 conventional 
knockout and endothelial-specific conditional knockout mice (Adams et al., 1999; Gerety 
and Anderson, 2002; Wang et al., 1998); however, the mutant mice die around E10 when 
ephrin-B2 is not yet expressed in arterial SMCs, preventing the investigation of ephrin-
B2 function in the SMCs, using the mutant mice.  The essential function of ephrin-B2 in 
endothelial cells during cardiovascular development suggests that ephrin-B2 may play an 
important role in SMCs as well.  However, the late onset of ephrin-B2 expression in 
arterial SMCs suggest ephrin-B2 function in SMCs might be different from that in 
endothelial cells where ephrin-B2 is expressed during early vascular development.   
This remaining question can be investigated by utilizing ephrin-B2 conditional 
knockout mice and smooth muscle-specific Cre deleter mice.  Ephrin-B2 conditional 
knockout mice were generated by Dr. Gerety in my lab (Gerety and Anderson, 2002); 
two transgenic smooth muscle-specific Cre deleter lines, SMMHC-Cre and SM22α-Cre, 
are available (Holtwick et al., 2002; Regan et al., 2000).  SMMHC-Cre mediated deletion 
of ephrin-B2 in arterial SMCs did not reveal any defects in the mutant mice.  The careful 
analysis of the Cre activity of the transgenic SMMHC-Cre line revealed that the 
SMMHC-Cre mediated recombination occurred in a very small number of arterial 
smooth muscle cells at E15.5 (Fig. 1A-C), indicating that this Cre line is not useful.  
However, SM22α-Cre mediated recombination extensively occurs in arterial SMCs but 
not in endothelial cells at E13.5 (Fig. 1D-F), suggesting that it is worth while to use a 
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SM22α-Cre deleter line to specifically remove ephrin-B2 in SMCs but not in endothelial 
cells. 
 
Fig. 1. SMMHC-Cre and SM22α-Cre mediated recombination in the dorsal aorta 
 
What controls the initiation of ephrin-B2 expression in arterial SMCs?  
VEGF and Notch signaling are involved in ephrin-B2 induction in arterial endothelial 
cells (Weinstein and Lawson, 2002), while the signal to induce the expression of ephrin-
B2 in arterial SMCs remains elusive.  Several Notch receptors and ligands are expressed 
in arterial SMCs as well as in arterial endothelial cells (Villa et al., 2001), suggesting that 
Notch signaling might be involved in ephrin-B2 induction in arterial SMCs like it induces 
ephrin-B2 expression in endothelial cells.  Since conventional knockouts of these genes 
result in early embryonic lethality due to their essential roles in endothelial cells, such 
knockout mice cannot be used to address this question.  Instead, the conditional knockout 
approach is applicable to the question, by specifically deleting the genes in SMCs but not 
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in endothelial cells using SM22α-Cre deleter line.  Notch1 conditional knockout mice are 
available (Limbourg et al., 2005), but the conditional knockout mice of other Notch 
receptors and ligands have to be generated to address the question. 
Neuropilin-1 (NP-1) is expressed in SMCs as well as in endothelial cells (Mukouyama 
et al., 2002; Yuan et al., 2002); therefore, the same approach suggested for Notch 
signaling could be applied to address whether NP-1-mediated VEGF signaling is 
involved in ephrin-B2 induction in SMCs.  In addition, conventional NP-1 knockout mice 
die around E13.5, allowing me to assess whether ephrin-B2 induction in arterial SMCs at 
E12.5-E13.5 is affected in the knockout mice.   
 
Ephrin-B2 functions in adult stable vasculature and neovasculature 
Although ephrin-B2 is essential for angiogenesis during embryonic development, it is not 
clear whether ephrin-B2 still plays an important role in adult vasculature.  The 
observation that ephrin-B2 is maintained in adult arterial endothelial cells, and expressed 
in a subset of endothelial cells in tumors, during wound healing, and in the corneal 
micropocket assay suggests that ephrin-B2 may play an important role in adult 
vasculature (Gale et al., 2001; Shin et al., 2001).   
This issue can be addressed by conditional knockout of ephrin-B2 in adults.  The 
endothelial-specific, temporal control of Cre activity can be achieved by the use of 
inducible Cre-ER (cre recombinase-estrogen receptor fusion), which is only active in the 
presence of estrogen analog tamoxifen (Danielian et al., 1998; Kellendonk et al., 1996), 
under an endothelial specific promoter such as Flk1, Tie2, or Scl.  Tie2-Cre-ER and Scl-
Cre-ER mice are available (Forde et al., 2002; Gothert et al., 2004), and Scl-Cre-ER 
   135
mediated recombination occurs in the endothelial cells of most adult tissues including 
tumors (Gothert et al., 2004).  This temporal, spatial ablation of ephrin-B2 mediated by 
Tie2-Cre-ER or Scl-Cre-ER will reveal the function of ephrin-B2 in endothelial cells in 
adult tissues.  In addition, using inducible Cre-ER under the promoter of pan-neovascular 
markers, such as D1.1, the function of ephrin-B2 in adult neovasculature could be 
investigated.  However, the Cre-ER mice still need to be generated in order to perform 
these experiments. 
If these studies demonstrate that ephrin-B2 is essential for adult vasculature and/or 
neovasculature, ephrin-B2 mediated signaling may serve as a useful target for therapeutic 
intervention. 
 
Further application of the differential screening method 
The differential screening method, which I used to isolate arterial specific genes from a 
small number of endothelial cells has several advantages over other differential screening 
methods.  First, a small number of cells (about 10-100 cells) are sufficient for this screen; 
therefore, this screen is applicable to the case where it is impossible to isolate a large 
number of cells (more than 500 cells).  Second, low abundant genes can be isolated by 
the subsequent subtraction of high abundant genes, identified in the previous subtraction, 
from cDNA libraries containing both high and low abundant genes.  This subsequent 
subtraction followed by PCR amplification can further increase the number of cDNAs of 
low abundant genes in the cDNA libraries.  Low abundant genes are not usually detected 
in a differential screen without subsequent enhancement of their signals; therefore, such 
enhancement is essential for detecting low abundant genes in a differential screen.  If 
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these two points are crucial for studies involving a differential screen, this method may 
be a good choice. 
This method can be used to isolate more markers to distinguish arterial SMCs from 
venous SMCs.  Although no SMC-specific antibodies are available for fluorescence 
activated-cell sorter (FACS), arterial and venous SMCs can be isolated by sorting 
PECAM-1 negative populations from umbilical arteries and veins, respectively.  The 
isolation and characterization of novel arterial or venous SMC-specific genes will 
improve the understanding of cardiovascular developments as well as the functions of 
vascular SMCs like those of endothelial-specific genes greatly improve the understanding 
of cardiovascular development. 
 
Significance of the molecular heterogeneity of arterial endothelial cells revealed by 
Depp 
Although the detailed analysis of Depp expression at E9.5 dorsal aorta reveals the 
molecular heterogeneity of arterial endothelial cells in a single vessel, the significance of 
this heterogeneity remains elusive.  Whether the heterogeneity of Depp expression is 
essential for proper vascular development can be tested by ectopically expressing DEPP 
in arterial endothelial cells under ephrin-B2 promoter.  This genetic approach will result 
in the homogeneous expression of DEPP in arterial endothelial cells, permitting us to 
investigate any significance of the heterogeneous expression of Depp.  In addition, I can 
investigate the significance of arterial-restricted expression of Depp by ectopically 
expressing DEPP in all endothelial cells under a pan-endothelial promoter such as Tie2 or 
PECAM-1.   
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To get more clues about the significance of the heterogeneity, gene expression profiles 
of Depp+ and Depp- arterial endothelial cells could be compared with each other.  I 
purified Depp+ and Depp- endothelial cells from the whole E10 embryos, and compared 
their gene expression profiles.  Several known arterial specific genes were enriched in 
Depp+ endothelial population; a known lymphatic marker, LYVE-1, was highly enriched 
in Depp- endothelial population.  However, these experiments did not provide any clues 
about the significance.  Depp- endothelial population contains a subset of arterial 
endothelial cells, all venous endothelial cells, all lymphatic endothelial cells, and maybe 
progenitor cells negative for Depp.  The complexity of Depp- endothelial population 
might result in various differences in gene expression profiles, preventing me from 
deducing any clues.  Furthermore, the use of the whole embryos, containing various types 
of vessels such as large, medium, and small vessels, could mask any differences that are 
specifically associated with one of these populations.  Therefore, the use of Depp+ and 
Depp- arterial endothelial cells from E9.5-E10 dorsal aorta of DeppEGFP/+;ephrin-B2lacZ/+ 
double heterozygous embryos will reduce the complexity in each population and increase 
the specific differences related to Depp expression.  Any clues deduced from this 
approach will serve as a starting point to investigate the functional significance of the 
heterogeneity in detail. 
 
Distinction between primary and secondary defects in cardiovascular development 
Most homozygous mutant mice, showing severe angiogenesis defects in embryos and 
yolk sacs, display severe heart defects.  The genes responsible for these phenotypes are 
typically expressed in both peripheral endothelial cells and endocardial cells, suggesting 
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their essential roles in endothelial and endocardial cells, respectively.  However, the fact 
that targeted deletion of heart-specific genes such as Nkx2.5 and MLC2a (atrial myosin 
light chain 2) (Huang et al., 2003; Tanaka et al., 1999), which are not expressed in 
peripheral endothelial cells, results in peripheral angiogenesis defects as well as heart 
defects, indicates that the peripheral angiogenesis defects in these mutant mice are 
secondary to the heart defects.   If any mutant mice display both peripheral angiogenesis 
defects and heart defects, it should be carefully considered whether these defects are 
primary or secondary defects. 
Depp is expressed in peripheral endothelial cells, but not in the endocardial cells of the 
heart; furthermore, Depp-Cre knockin mice reveal that Depp-Cre mediated 
recombination does not occur in atrial or ventricular endocardial cells of the heart (as 
described in Chapter 2).  This unique expression pattern allows Depp-Cre mice to be used 
as a Cre deleter line to specifically remove genes in peripheral endothelial cells but not in 
heart endocardial cells.  By deleting genes, expressed in both peripheral endothelial and 
heart endocardial cells, only in peripheral endothelial cells, the function of the genes in 
peripheral endothelial cells can be investigated without being affected by heart defects. 
Ephrin-B2 conventional knockout and endothelial specific knockout mice show the 
same angiogenesis and heart defects; ephrin-B2 is expressed in both peripheral 
endothelial cells and heart endocardial cells.  Therefore, it is not clear whether the 
peripheral angiogenesis defects in the mutant reflect a local requirement for ephrin-B2 
signaling, or rather are secondary to the heart defects.  I used the Depp-Cre line and a 
conditional ephrin-B2 allele, in order to distinguish whether the peripheral angiogenesis 
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defects is primary or secondary to the heart defects.  The detailed analysis and data are 
described in the Appendix.   
Although the Depp-Cre deleter line is useful in terms of peripheral endothelial 
specificity, the Cre-mediated recombination occurs in a subset of arterial endothelial cells, 
and the number of recombination-occurring cells varies among different embryos.  I 
recently found that connexin40 (Cx40), a gap junction protein, is expressed in arterial 
endothelial cells but not in endocardial cells like Depp.  In addition, Cx40 is expressed in 
most arterial endothelial cells, while Depp is expressed in a subset of arterial endothelial 
cells, suggesting that Cx40-Cre-mediated recombination might occur in most arterial 
endothelial cells, and the number of recombination-occurring cells might be similar 
among different embryos.  Thus, it is worthwhile to generate Cx40-Cre mice, serving as a 
useful arterial-specific Cre deleter line. 
 
D1.1 monoclonal antibody production 
Since D1.1 may be a useful marker of adult neovasculature, the generation of monoclonal 
antibodies would be valuable for diagnosis of neovascularization and for drug targeting to 
neovasculature.   
Mouse monoclonal antibodies to mouse D1.1 can be generated using D1.1 
homozygous mutant mice lack of any phenotypic defects.  The mutant mice do not 
produce D1.1 proteins; thus, they recognize mouse D1.1 proteins as a foreign antigen, 
initiating antibody production.  By injecting mouse D1.1-Fc proteins, that I used for in 
vivo and in vitro angiogenesis assays, into the homozygous mutant mice, and by 
subsequently testing specific binding of antibodies in hybridoma supernatants on cells 
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transfected with mouse D1.1 expression plasmids, mouse monoclonal antibodies to 
mouse D1.1 might be generated and selected.  
In addition, mouse monoclonal anti-human D1.1 antibodies could be generated in a 
similar way to anti-mouse D1.1 antibodies, by injecting human D1.1-Fc proteins into 
wild-type or the homozygous mutant mice and the subsequent testing.  If the expression 
pattern of human D1.1 is similar to that of mouse D1.1, anti-human D1.1 antibodies 
could be useful to detect neovessels in human samples.  Furthermore, the antibodies 
could be used to deliver conjugated drugs into the endothelial cells of neovasculature. 
 
Overexpression studies of D1.1 
Despite the absence of any phenotypic defects in D1.1 homozygous mutant mice, the 
overexpression of D1.1 in all endothelial cells might reveal the function of D1.1 in 
cardiovasculature.  D1.1 is barely expressed in the veins of embryonic yolk sacs, and is 
barely or weakly expressed in the microvessels of most adult tissues.  The mis-expression 
of D1.1 under a pan-endothelial promoter, such as Flk1, Tie-2, or PECAM-1, would yield 
homogeneous D1.1 expression in all endothelial cells during development and in 
adulthood.  If the absence and down-regulation of D1.1 expression in the veins of yolk 
sacs and in the microvessels of adult tissues, respectively, are essential for proper vessel 
development or maintenance of vessel integrity, the gain-of-function studies might reveal 
the function of D1.1, which can not be observed by loss-of-function studies. 
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Acute loss-of-function studies of D1.1 in vitro 
Although D1.1-Fc acts as an angiogenic inhibitor in several angiogenic assays, it is not 
clear whether it is an agonist or antagonist of D1.1, making it hard to conclude an actual 
function of D1.1 based on D1.1-Fc activity.  Any phenotypic defects in D1.1 
homozygous mutant mice will clarify the issue, but there are no such defects in the 
mutant mice. 
From the beginning of development, D1.1 is absent in D1.1 homozygous mutant mice; 
therefore, it is possible that the homozygous mutant mice might have built up 
mechanisms to compensate for lack of D1.1.  If this is the reason that the homozygous 
mutants appear phenotypically normal, the acute deletion of D1.1 might reveal the 
function of D1.1, by depriving endothelial cells from sufficient time to compensate for 
lack of D1.1.  The acute deletion of D1.1 can be achieved through RNAi approach using 
HUVEC cells, whose general and VEGF-induced migration is significantly reduced in 
the presence of D1.1-Fc.  If the acute deletion reduces the migration of HUVEC cells, 
D1.1-Fc acts as an antagonist, and the actual function of D1.1 is pro-angiogenic.  If the 
acute deletion enhances the migration of HUVEC cells, D1.1-Fc acts as an agonist, and 
the actual function of D1.1 is anti-angiogenic. 
 
 
   142
REFERENCES 
 
 
Adams, R. H., Wilkinson, G. A., Weiss, C., Diella, F., Gale, N. W., Deutsch, U., Risau, 
W., and Klein, R. (1999). Roles of ephrinB ligands and EphB receptors in 
cardiovascular development: demarcation of arterial/venous domains, vascular 
morphogenesis, and sprouting angiogenesis. Genes & Development 13, 295-306. 
Danielian, P. S., Muccino, D., Rowitch, D. H., Michael, S. K., and McMahon, A. P. 
(1998). Modification of gene activity in mouse embryos in utero by a tamoxifen-
inducible form of Cre recombinase. Current Biology 8, 1323-1326. 
Forde, A., Constien, R., Grone, H. J., Hammerling, G., and Arnold, B. (2002). Temporal 
Cre-mediated recombination exclusively in endothelial cells using Tie2 regulatory 
elements. Genesis 33, 191-197. 
Gale, N. W., Baluk, P., Pan, L., Kwan, M., Holash, J., DeChiara, T. M., McDonald, D. 
M., and Yancopoulos, G. D. (2001). Ephrin-B2 selectively marks arterial vessels 
and neovascularization sites in the adult, with expression in both endothelial and 
smooth-muscle cells. Developmental Biology 230, 151-160. 
Gerety, S. S., and Anderson, D. J. (2002). Cardiovascular ephrinB2 function is essential 
for embryonic angiogenesis. Development 129, 1397-1410. 
Gothert, J. R., Gustin, S. E., van Eekelen, J. A. M., Schmidt, U., Hall, M. A., Jane, S. M., 
Green, A. R., Gottgens, B., Izon, D. J., and Begley, C. G. (2004). Genetically 
tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to 
tumor endothelium. Blood 104, 1769-1777. 
Holtwick, R., Gotthardt, M., Skryabin, B., Steinmetz, M., Potthast, R., Zetsche, B., 
Hammer, R. E., Herz, J., and Kuhn, M. (2002). Smooth muscle-selective deletion 
   143
of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood 
pressure. Proceedings of the National Academy of Sciences of the United States of 
America 99, 7142-7147. 
Huang, C. Q., Sheikh, F., Hollander, M., Cai, C. L., Becker, D., Chu, P. H., Evans, S., 
and Chen, J. (2003). Embryonic atrial function is essential for mouse 
embryogenesis, cardiac morphogenesis and angiogenesis. Development 130, 
6111-6119. 
Kellendonk, C., Tronche, F., Monaghan, A. P., Angrand, P. O., Stewart, F., and Schutz, 
G. (1996). Regulation of cre recombinase activity by the synthetic steroid RU 486. 
Nucleic Acids Research 24, 1404-1411. 
Limbourg, F. P., Takeshita, K., Radtke, F., Bronson, R. T., Chin, M. T., and Liao, J. K. 
(2005). Essential role of endothelial Notch1 in angiogenesis. Circulation 111, 
1826-1832. 
Mukouyama, Y., Shin, D., Britsch, S., Taniguchi, M., and Anderson, D. J. (2002). 
Sensory nerves determine the pattern of arterial differentiation and blood vessel 
branching in the skin. Cell 109, 693-705. 
Regan, C. P., Manabe, I., and Owens, G. K. (2000). Development of a smooth muscle-
targeted cre recombinase mouse reveals novel insights regarding smooth muscle 
myosin heavy chain promoter regulation. Circulation Research 87, 363-369. 
Shin, D., Garcia-Cardena, G., Hayashi, S. I., Gerety, S., Asahara, T., Stavrakis, G., Isner, 
J., Folkman, J., Gimbrone, M. A., and Anderson, D. J. (2001). Expression of 
ephrinB2 identifies a stable genetic difference between arterial and venous 
vascular smooth muscle as well as endothelial cells, and marks subsets of 
   144
microvessels at sites of adult neovascularization. Developmental Biology 230, 
139-150. 
Tanaka, M., Chen, Z., Bartunkova, S., Yamasaki, N., and Izumo, S. (1999). The cardiac 
homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential 
for heart development. Development 126, 1269-1280. 
Villa, N., Walker, L., Lindsell, C. E., Gasson, J., Iruela-Arispe, M. L., and Weinmaster, G. 
(2001). Vascular expression of Notch pathway receptors and ligands is restricted 
to arterial vessels. Mechanisms of Development 108, 161-164. 
Wang, H. U., Chen, Z. F., and Anderson, D. J. (1998). Molecular distinction and 
angiogenic interaction between embryonic arteries and veins revealed by ephrin-
B2 and its receptor Eph-B4. Cell 93, 741-753. 
Weinstein, B. M., and Lawson, N. D. (2002). Arteries, veins, notch, and VEGF. Cold 
Spring Harbor Symposia on Quantitative Biology 67, 155-162. 
Yuan, L., Moyon, D., Pardanaud, L., Breant, C., Karkkainen, M. J., Alitalo, K., and 
Eichmann, A. (2002). Abnormal lymphatic vessel development in neuropilin 2 
mutant mice. Development 129, 4797-4806. 
 
   145
 
Appendix 
 
 
Specific Deletion of Ephrin-B2 in Peripheral Endothelial Cells, but not in Heart 
Endocardial Cells Reveals an Essential Role of Ephrin-B2 in Peripheral 
Endothelial Cells 
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Ephrin-B2 conventional knockout and endothelial specific knockout mice show the same 
angiogenesis defects in head, trunk and yolk sac as well as the same heart defects during 
embryonic development (Gerety and Anderson, 2002; Wang et al., 1998); ephrin-B2 is 
expressed in both peripheral endothelial cells and heart endocardial cells (Gerety and 
Anderson, 2002; Wang et al., 1998), suggesting that the defects in peripheral vasculature 
and the heart result from the absence of ephrin-B2 in peripheral endothelial and heart 
endocardial cells, respectively.  However, the fact that targeted deletion of heart-specific 
genes such as Nkx2.5 and MLC2a (atrial myosin light chain 2) (Huang et al., 2003; 
Tanaka et al., 1999), which are not expressed in peripheral endothelial cells, results in 
peripheral angiogenesis defects as well as heart defects indicates that the peripheral 
angiogenesis defects in these mutant mice are secondary to the heart defects.  Therefore, 
it is not clear whether the peripheral angiogenesis defects in ephrin-B2 conventional 
knockout and endothelial specific knockout mice reflect a local requirement for ephrin-
B2 signaling, or rather may be secondary to the heart defects.   
To address this issue, I generated a novel Cre line by inserting an EGFP-Cre fusion 
construct into the locus of Depp that is expressed in peripheral arterial endothelial cells, 
but not in endocardial cells, as described in Chapter 2.  Using this Cre line and a 
conditional ephrin-B2 allele, I have deleted ephrin-B2 in peripheral endothelial cells but 
not in atrial or ventricular endocardial cells of the heart.  Apparently 45% of the 
conditional ephrin-B2 mutants show severe angiogenesis defects in head, trunk, and yolk 
sac as well as heart defects at E9.5 (Fig. 1).  About 45% penetrance of the phenotypes 
may stem from the variable Cre activity which I observed in Depp-Cre;Rosa26R double 
heterozygous embryos and yolk sacs by β-gal expression pattern (Fig. 2).  The 
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angiogenesis defects in the conditional mutants are similar to those in ephrin-B2 
conventional mutants.  However, endocardial cells in the conditional mutants display 
normal  trabeculation in the right ventricle (Fig. 1J, arrows), whereas endocardial 
trabeculation is greatly reduced in the conventional mutants (Gerety and Anderson, 2002; 
Wang et al., 1998), suggesting that ephrin-B2 in ventricular endocardial cells is required 
for the endocardial trabeculation. 
The detailed analysis of Depp-Cre activity and ephrin-B2 expression in the heart 
reveals that Depp-Cre mediated recombination occurs in a subset of endocardial and 
myocardial cells of the outflow tract (Fig. 3D-F), and ephrin-B2 is expressed in the 
endocardial and myocardial cells of the outflow tract but barely expressed in myocardial 
cells of the atria and ventricles (Fig. 3A-C, and data not shown).  Therefore, it is not clear 
whether the severe heart defects and the angiogenesis defects witnessed in the half of the 
conditional mutants at E9.5 are caused by ephrin-B2 deletion in peripheral endothelial 
cells or by the deletion in the endocardial and/or myocardial cells of the outflow tract.   
To clarify this issue, several other Cre lines, which are active in the heart but not in 
peripheral endothelial cells, were used to delete ephrin-B2 specifically in the heart.  Isl1-
Cre is active in a subset of endocardial and myocardial cells of the outflow tract and in a 
subset of myocardial cells in the rest of the heart (Cai et al., 2003); SM22α-Cre (Holtwick 
et al., 2002) and Nkx2.5-Cre (Moses et al., 2001) are active in most of the myocardial 
cells throughout the heart; and αMHC-Cre (Gaussin et al., 2002) is active in most of the 
myocardial cells of the atria and ventricles, but not in the outflow tract (Fig. 3G-R).  
None of these Cre-mediated ephrin-B2 conditional knockout mice display any 
angiogenesis or heart defects at E9.5, suggesting that ephrin-B2 in the endocardial cells 
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of the outflow tract and in the myocardial cells of the entire heart may be not essential for 
proper cardiovascular development at least until E9.5.  However, the fact that the number 
of Isl1-Cre positive endocardial cells in the outflow tract is lower than that of Depp-Cre 
positive endocardial cells (Fig. 3G, H vs D, E) makes it unclear whether ephrin-B2 
deletion in the endocardial cells of the outflow tract contributes to the peripheral 
angiogenesis defects.  To clarify this point, another Cre line, active in most endocardial 
cells of the outflow tract but not in the endocardial cells of the atria or the ventricles, 
should be used.  I am using a novel Cre line, NFATc1-Cre (Zhou et al., 2005), which may 
be active in the endocardial cells of the outflow tract and the atrioventricular canal but 
not in the atrial or ventricular endocardial cells, to clarify this issue.   
At this point, I can not exclude the possibility that ephrin-B2 deletion in the 
endocardial cells of the outflow tract causes peripheral angiogenesis defects; however, 
these data suggest that the angiogenesis defects in ephrin-B2 conventional knockout mice 
are not due to the deletion in atrial or ventricular endocardial cells, or in the myocardial 
cells of the entire heart including the outflow tract. 
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Fig. 1 Depp-Cre mediated ephrin-B2 conditional knockout mice display peripheral 
angiogenesis defects as well as heart defects at E9.5 
 
 
 
 
 
 
Fig. 2 Variegation of Depp-Cre mediated recombination 
 
   150
 
 
Fig. 3 Ephrin-B2 expression and several Cre activities in the outflow tract at E9.5
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